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Approximately 2.1 million people in the United States suffer from opioid use disorder, 
and over 47,600 people die from opioid-related overdoses each year. Opioid overdose is 
often treated with naloxone, a quick-acting medication that counteracts the effects of an 
overdose. This quantitative, correlational study was conducted to determine whether 
demographics (gender, age, and race) and naloxone accessibility were predictors of 
repeat opioid overdose in a Tennessee county in the United States. The study was 
developed and conducted using principles of the diffusion of innovations theory. 
Descriptive and inferential analyses were conducted using secondary, county-level data 
(n = 967) from emergency medical services (EMS) overdose rescues and a community-
based naloxone education and distribution program. Results of multiple logistic 
regression and Poisson regression analyses indicated gender was the only demographic 
variable to be a statistically significant predictor of repeat opioid overdose. The odds ratio 
of females was .37 times that of males, indicating females were 63% less likely to 
experience a repeat opioid overdose compared to males (p = .02). Naloxone accessibility, 
as measured by the distribution of naloxone kits through the community-based program 
and the naloxone dose administered by EMS first responders, was not a statistically 
significant predictor of repeat opioid overdose. The results of this study could be used to 
craft appropriate interventions to minimize overdose mortality statistics and curtail the 
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Chapter 1: Introduction to the Study 
Opioid overdose, which can be nonfatal or fatal, is a daunting public health 
concern affecting individuals globally. Although approaches such as multidisciplinary 
treatment and prevention efforts are underway to address the problem, opioid-related 
morbidity and mortality rates continue to rise (Blanco & Volkow, 2019). Fatal and 
nonfatal opioid overdoses are often associated with opioid use disorder, which is the 
continual use of opioids despite their adverse effects, resulting in a spectrum of mental, 
physical, and social problems (Blanco & Volkow, 2019). The disorder involves cravings 
to use opioids, increased tolerance to usual dose of opioids, and withdrawal symptoms 
when attempting to reduce or cease the use of opioids (Blanco & Volkow, 2019). In 
2016, approximately 27 million people worldwide suffered from opioid use disorder, and 
118,000 opioid overdose deaths were attributed to such disorders (World Health 
Organization [WHO], 2018). Approximately 2.1 million people in the United States 
suffer from the disorder, and 130 people die each day from opioid-related overdose (U.S. 
Department of Health and Human Services [HHS], Substance Abuse and Mental Health 
Services Administration [SAMHSA], 2018). The severity of the opioid overdose problem 
in the United States led to its declaration as a national public health emergency by the 
nation’s president in October 2017 (The White House, n.d.). 
Two types of opioids are associated with the current opioid overdose crisis: 
prescription opioid pain relievers and illicit opioids. The pain-relieving opioids are 
categorized as natural, semisynthetic, or synthetic (Centers for Disease Control and 
Prevention [CDC], 2018). Natural opioids are derivatives of opium poppy and include 
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such drugs as codeine and morphine (CDC, 2018). Semisynthetic opioids are synthesized 
from natural opioids and include prescription drugs such as hydrocodone and oxycodone 
(CDC, 2018; Seither & Reidy, 2017). Synthetic opioids are made in laboratories, are 
highly potent, and may not have a similar chemical structure as natural opioids, although 
they are designed to produce the same effect as natural opioids (Seither & Reidy, 2017). 
Fentanyl, methadone, and tramadol are examples of synthetic opioids (CDC, 2018). The 
pain-relieving opioids are licit because they are prescribed legally by physicians in the 
treatment of pain. 
Illicit opioids are prohibited by law. Such opioids include heroin, which is 
synthetic, and illegally manufactured synthetic opioids such as fentanyl and carfentanil, a 
derivative/analog of fentanyl (CDC, 2018; HHS, National Institutes of Health [NIH], 
National Institute on Drug Abuse [NIDA], n.d.-a). All opioids are agonists that activate 
the opioid receptors—particularly the mu receptor—in the brain, causing the increased 
release of dopamine, which triggers the rewarding or feel-good effects of the drug 
(Kreek, 2002). The interaction is illustrated in Figure 1. The feeling of euphoria caused 
by opioids makes them extremely addictive, which can lead to opioid use disorder or a 




Figure 1. Effect of opioid use on the brain. 
In 2017, opioids were involved in 47,600 drug overdose deaths in the United 
States (Scholl, Seth, Kariisa, Wilson, & Baldwin, 2019). The use of prescription opioids 
was attributable to 35.8% of these deaths (Scholl et al., 2019). Synthetic opioids 
(excluding methadone) and the illicit opioid heroin were attributable to 59.8% and 
32.5%, respectively, of the opioid-related deaths (Scholl et al., 2019). Over 142,500 
people visited emergency departments between July 2016 and September 2017 as a result 
of opioid-related overdose, a rate of 15.7 per 10,000 visits (Vivolo-Kantor et al., 2018). 
During this same observation period, the emergency department visits involving opioid 
overdose increased by 29.7% (Vivolo-Kantor et al., 2018). Monitoring these opioid 
overdose statistics is only one method of attempting to quantify the extent of the nation’s 
opioid epidemic (Warfield, Pollini, Stokes, & Bossarte, 2019). Examining the nature of 
repeat overdose, which is the focus of this study, is also important. Such information can 
help provide needed metrics regarding the potency of opioids being used illicitly and the 
efficacy of naloxone, which is used to reverse the effects of an overdose (Warfield et al., 
2019). Such data can also be used to craft policies and programs designed to alter the 
behavior of opioid misuse, thereby reducing opioid-related illnesses and deaths. 
4 
 
The background information regarding opioid overdose, the problem statement, 
and the purpose of the study are discussed in this chapter. Next, the research questions, 
along with their respective hypotheses, and the theoretical framework are discussed. 
Finally, the nature of the study, the definitions, the assumptions, and the scope and 
delimitations of the study are discussed. 
Background 
To understand the current status of the opioid overdose problem in the United 
States, it is necessary to understand several previous events and current factors associated 
with the public health issue. Discussions regarding the nation’s progression of opioid 
overdose mortality and risk factors associated with the problem are included in this 
section. Detailed information about naloxone and its accessibility and role in the 
prevention of opioid overdose are also presented. Lastly, a discussion of the knowledge 
gap associated with the research topic and why this current study was necessary are 
presented. 
Progression of Opioid Overdose Mortality 
Seth, Scholl, Rudd, and Bacon (2018) observed that the United States is 
experiencing the third wave of opioid overdose deaths. The first wave began in the 1990s 
with prescription opioids at the forefront of the overdose crisis (Seth et al., 2018). By 
2010, U.S. physicians were prescribing opioids at a rate of 81.2 prescriptions per 100 
patients (Guy et al., 2017). The historic overprescribing of opioid pain relievers is 
believed to be the source of the current opioid epidemic, as many people became addicted 
to opioids (Kolodny et al., 2015). The prevalent availability of the pain relievers made 
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them easily accessible by individuals who used the drugs for nonmedical reasons 
(Compton, Jones, & Baldwin, 2016; Kolodny et al., 2015). Many of the people who 
became addicted to prescription opioids and lacked access to them (i.e., discontinued 
prescription or unable to afford the pharmaceuticals) often turned to heroin as a substitute 
(Compton et al., 2016; Kolodny et al., 2015). 
Pharmacologically, heroin has the same effect as prescription pain relievers, and it 
is cheaper, which makes it attractive to those who abuse opioids (Compton et al., 2016). 
Heroin became the prominent opioid associated with the second wave of overdose 
fatalities that began in 2010 (Seth et al., 2018). Law enforcement reports indicated that 
heroin use increased continually in the United States from 2006 to 2015 (O’Donnell, 
Gladden, & Seth, 2017). The fatality rate involving heroin increased during this period as 
well, with a more pronounced increase observed between 2010 and 2015 (O’Donnell et 
al., 2017). In 2010, heroin overdose claimed the lives of 3,036 U.S. individuals 
(O’Donnell et al., 2017). By 2015, the annual death toll had quadrupled to 12,989 
(O’Donnell et al., 2017). After 2013, many of the heroin-related deaths were associated 
with illicit fentanyl, which is much more potent than heroin (O’Donnell et al., 2017). 
Drug traffickers began adding fentanyl to their heroin supplies, creating an extremely 
deadly combination (O’Donnell et al., 2017). 
The third wave of opioid overdose deaths began in 2013 and has been driven by 
the prevalent misuse of extremely potent synthetic opioids (O’Donnell et al., 2017; Seth 
et al., 2018). From 2014 to 2015, the rate of overdose deaths involving synthetic opioids 
increased by 72.2% from 1.8 to 3.1 deaths per 100,000 population (Rudd, Seth, David, & 
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Scholl, 2016). Fentanyl was the main opioid associated with the rise in opioid overdose-
related deaths. Fentanyl is classified as a Schedule II drug, meaning it has a high risk of 
abuse and is likely to cause physical or psychological dependence (U.S. Drug 
Enforcement Agency, n.d.). Compared to morphine, fentanyl is approximately 100 times 
more potent (Volpe et al., 2011). Analogs of fentanyl, such as carfentanil, can be as much 
as 100 times more potent than fentanyl and 10,000 times more potent than morphine 
(HHS, NIH, National Library of Medicine [NLM], n.d.-a). Carfentanil was synthesized to 
be used as an anesthetic for large animals and not for use in humans (HHS, NIH, NLM, 
n.d.-a). However, between July 2016 and June 2017, carfentanil was detected in 1,236 
people who died from opioid overdose (O’Donnell, Gladden, Mattson, & Kariisa, 2018). 
The use of carfentanil and other illicitly manufactured fentanyls has been at the center of 
recent increasing outbreaks of opioid overdose deaths (O’Donnell et al., 2018). The 
emergence of these illicit drugs represents an added component to the current opioid 
epidemic with which law enforcement, health, and public health personnel must contend. 
Recent surveillance data indicated that opioid-related deaths are increasing. The 
increase, according to O’Donnell et al. (2017), continues to be attributed to illegally 
produced fentanyl and its analogs. The rate of death from all opioids increased from 13.3 
to 14.9 deaths per 100,000 from 2016 to 2017 (Scholl et al., 2019). Overdose fatalities 
involving synthetic opioids increased from 6.2 to 9.0 deaths per 100,000 population from 
2016 to 2017, which was cause for alarm as the fatalities represented a 45.2% increase in 
just 1 year (Scholl et al., 2019). During this same period, prescription pain relievers and 
heroin continued to contribute to the opioid epidemic with stabilized overdose death rates 
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of 5.2 and 4.9 per 100,000, respectively (Scholl et al., 2019). Prevention efforts are 
necessary to minimize these statistics and to help control the opioid overdose crisis. For 
such efforts to be effective, it is important that public health practitioners understand the 
populations affected by the problem. 
Opioid Overdose Risks Factors 
There are overdose risk factors associated with the use of licit prescription opioids 
(i.e., pain relievers) and illicit opioids (i.e., heroin and fentanyl). The risk factors of 
overdose among users of prescription pain relievers include older age, lower 
socioeconomic status, being male, multiple prescriptions for pain relievers, and a history 
of mental illness or substance use disorder (WHO, 2018). Users of illicit opioids who are 
at risk of overdose tend to be male, 18 to 25 years of age, White, reside in metropolitan 
areas, and suffer from opioid, cocaine, marijuana, and alcohol use disorders (C. M. Jones, 
Logan, Gladden, & Bohm, 2015). 
People who are at greater risk of opioid overdose include those who suffer from 
opioid use disorder, use opioids intravenously, take high doses of prescription opioids, 
combine fentanyl or its analogs with other opioids (i.e., heroin), combine opioids with 
other sedating drugs, or have a history of overdose (i.e., repeat overdose), psychiatric 
disorders, or suicide ideations (Blanco & Volkow, 2019). Opioid use disorder, which is 
the greatest risk of opioid overdose, has risk factors associated with it (WHO, 2018). 
Some of the factors include being male, younger in age, unemployed, having a history of 





Naloxone hydrochloride (commonly known as naloxone) is a synthetic derivative 
of oxymorphone and was discovered in 1961 (Handal, Schauben, & Salamone, 1983). As 
a medication, naloxone is quick acting in counteracting the effects of an opioid overdose 
(WHO, 2014). An overdose involves the excessive intake of a drug that causes bodily 
injury or death (American Society of Addiction Medicine, 2015). An opioid overdose 
manifests as pinpoint pupils, depression of the respiratory system, or loss of 
consciousness (Weaver, Palombi, & Bastianelli, 2018). Naloxone acts as an antagonist, 
competing with the opioid drug to bind the opioid receptor, thereby temporarily reversing 
the depressed respiration, sedation, and unconsciousness caused by the overdose (CDC, 
2018; Weaver et al., 2018). Administering naloxone as soon as possible to an individual 
experiencing an opioid overdose increases the individual’s chances of survival (ADAPT 
Pharma, n.d.; Heavey, Chang, et al., 2018). Because naloxone has an affinity for the mu 
opioid receptor in the brain, it rarely activates other receptors and, therefore, is ineffective 
for use with other nonopioid drugs such as cocaine or alcohol (Weaver et al., 2018). 
Naloxone is regulated as a prescription drug (Sherman et al., 2009). The 
medication is available in different forms for administration to an opioid overdose victim. 
The form approved by the Food and Drug Administration (FDA) in 1971 was for 
injection, which can be administered intravenously, intramuscularly, or subcutaneously 
(HHS, NIH, NLM, n.d.-b; Weaver et al., 2018). An intramuscular (or subcutaneous) auto-
injector form with the brand name Evzio® was approved by the FDA in 2014 (Weaver et 
al., 2018). In 2015, the FDA approved Narcan®, which is the brand name of a naloxone 
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nasal spray, for the use in reversing opioid overdose (WHO, 2015). As a form that is 
more user-friendly to laypersons, Narcan® offers the advantage of administration without 
the use of needles, thereby eliminating the risk of infections resulting from needle sticks 
(WHO, 2015). 
Naloxone is considered a relatively safe, innocuous pharmaceutical that does not 
have addictive properties (HHS, NIH, NLM, n.d.-b). There are, however, some adverse 
effects associated with the medication, including rare instances of hypertension, 
hypotension, pulmonary edema, cardiac arrest, and convulsions (HHS, NIH, NLM, n.d.-
b). Acute withdrawal syndrome, another adverse effect of the medication, is experienced 
more frequently in resuscitated individuals (McDonald & Strang, 2016). The condition 
occurs when the reversal of the opioid overdose is abrupt in individuals who are 
physically dependent on opioids (HHS, NIH, NLM, n.d.-b). Some of the symptoms often 
experienced during acute withdrawal syndrome include agitation, nausea, sweating, body 
aches, fever, and weakness (HHS, NIH, NLM, n.d.-b; McDonald & Strang, 2016). 
Considering its life-saving capability, the potential to precipitate a rare adverse effect or 
acute withdrawal syndrome is an acceptable trade-off. 
Naloxone Accessibility 
The continued misuse of prescription opioids and the proliferation of illicit 
opioids have necessitated legislation and policies addressing increased access to naloxone 
on a broad scale. Naloxone access refers to the possession of or ability to obtain naloxone 
to treat or prevent opioid overdose (Heavey, Chang, et al., 2018). On July 22, 2016, the 
U.S. Congress enacted the Comprehensive Addiction and Recovery Act (2016) in 
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response to the nation’s opioid epidemic. The Act authorized the Attorney General and 
Secretary of Health and Human Services to award grants to the states to help them 
establish or improve opioid overdose education and prevention initiatives, to provide 
opioid training to law enforcement personnel, and to improve access to opioid use 
disorder treatment and recovery (Comprehensive Addiction and Recovery Act, 2016). On 
April 5, 2018, the U.S. Surgeon General issued a public health advisory that urged 
Americans to learn how to administer naloxone and emphasized that the medication 
should be available when needed to prevent an opioid overdose (HHS, Office of the 
Surgeon General, 2018). The Surgeon General encouraged health care practitioners to 
review their state’s requirements regarding the use of standing orders or collaborative 
agreements and work with pharmacists in ensuring that individuals most at risk of opioid 
overdose and their friends and families can obtain naloxone (Adams, 2018). Additionally, 
the Surgeon General encouraged health care providers to adhere to the CDC’s opioid-
prescribing guidelines and learn the risk factors associated with opioid overdose (Adams, 
2018). Expanding the access to naloxone and implementing opioid prevention, treatment, 
and recovery programs were deemed crucial elements by the Surgeon General in helping 
to reduce opioid overdose mortality (HHS, Office of the Surgeon General, 2018). 
As of 2017, all 50 states and the District of Columbia had instituted legislation 
improving access to naloxone by laypersons, including family members and friends of 
the opioid users (Lewis et al., 2016; Network for Public Health Law, n.d.). Included 
among the laws and policies are Good Samaritan laws and provisions for naloxone 
standing orders and collaborative practice agreements. Good Samaritan legislation 
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provides immunity from criminal charges to individuals who witness and report an 
overdose event (McClellan et al., 2018). The objective of Good Samaritan laws is to save 
lives by encouraging bystanders who witness an opioid overdose to call for emergency 
medical services, even if they were also using opioids (Keane, Egan, & Hawk, 2018). 
Standing orders and collaborative practice agreements allow clinicians to designate other 
health care professionals as dispensers of naloxone without a patient-specific prescription 
(Adams, 2018; Davis & Carr, 2017). The orders and agreements expand the role of 
individuals such as pharmacists who occupy positions that can help in treating opioid 
overdose so that they can prescribe naloxone (Adams, 2018; Davis & Carr, 2017). 
Standing orders, collaborative practice agreements, and Good Samaritan laws are 
being adopted or transformed to ensure that individuals in need of naloxone have access 
to it (Davis & Carr, 2015). Currently, 47 states and the District of Columbia have 
standing orders and collaborative practice agreements that permit the prescribing and the 
dispensing of naloxone by pharmacists to individuals other than the person at risk of an 
opioid overdose (Network for Public Health Law, n.d.). The individuals can be family 
members or friends of the at-risk person. Statewide naloxone standing orders or 
collaborative practice agreements that allow laypersons to purchase naloxone in the form 
of Naran® from major pharmacy chains without a doctor’s prescription exist in every 
state (ADAPT Pharma, n.d.). As of 2018, Good Samaritan laws that provide at least some 
level of protection to individuals who, in good faith, report an opioid overdose from 
arrest or prosecutions exist in 46 states and the District of Columbia (Network for Public 
Health Law, n.d.). Legislation and policies like these can help achieve the Surgeon 
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General’s goal of expanding access to naloxone to at-risk opioid overdose populations. 
Increasing the accessibility of the medication to vulnerable populations may help reduce 
the pervasiveness of opioid-related deaths. 
Role of Naloxone in Opioid Overdose 
The FDA approved the use of naloxone in 1971 to treat respiratory depression 
caused by opioids (Faul et al., 2017). Emergency medical service (EMS) providers have 
used the medication for more than 30 years to treat overdose patients (Kim, Irwin, & 
Khoshnood, 2009). The rapid rise in opioid overdose deaths since 1999 prompted policy 
makers to include other professional emergency first responders, such as law enforcement 
officers (LEOs) and firefighters, in the efforts to expand the accessibility of naloxone to 
individuals in need of the medication (Davis, Carr, Southwell, & Beletsky, 2015; Davis, 
Ruiz, Glynn, Picariello, & Walley, 2014; O’Donnell et al., 2017). 
An analysis of 2012–2016 data by Cash et al. (2018) revealed a relationship 
between naloxone use and opioid-related fatalities in the United States. As the death rate 
increased by 79.7% from 7.4 to 13.3 deaths per 100,000 during the observation period, 
the number of naloxone administrations increased as well (Cash et al., 2018). From 2012 
to 2016, naloxone administrations by EMS personnel increased from 573.6 
administrations per 100,000 to 1,004.4, an increase of 75.1% (Cash et al., 2018). The 
North Carolina Harm Reduction Coalition (NCHRC, n.d.) estimated that by the end of 
2016, there were 1,216 law enforcement programs nationwide that had incorporated the 
use of naloxone in their emergency response practices. By November of 2018, the total 
number of programs nationally more than doubled, increasing to 2,482 (NCHRC, n.d.). 
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The increasing prevalence of naloxone administrations by emergency response 
professionals helps save lives by reversing the effects of an opioid overdose. However, it 
is not a solution to the addiction problem associated with opioids, which is a risk marker 
for repeat opioid overdose and opioid-related mortality (Haug, Bielenberg, Linder, & 
Lembke, 2016). 
Gap in Knowledge and Rationale for the Current Study 
As Heavey, Chang, et al. (2018) discussed, little is known about the effect of 
naloxone on opioid use behavior from a social and health perspective, thereby 
representing a gap in knowledge. The current study, which included an examination of 
the correlation between demographics, naloxone accessibility (as measured by the doses 
administered by professional first responders and naloxone rescue kits distributed via a 
community naloxone program), and repeat overdose, may help fill the gap in knowledge. 
This study may help quantify the relationship between repeat overdose and naloxone 
accessibility, and it may help determine whether the accessibility of naloxone has an 
impact on repeat overdose. Health and public health practitioners may use the results to 
understand the depth of the opioid epidemic. Additionally, the findings may be useful in 
crafting appropriate interventions to minimize overdose mortality statistics and curtail the 
deadly opioid epidemic. 
Problem Statement 
Opioids are valuable in managing pain associated with cancer, surgery recovery, 
and other medical conditions. Their use, however, involves risks that include misuse, 
opioid use disorder, overdose, and death (Dowell, Haegerich, & Chou, 2016). Globally, 
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the annual incidence of fatal opioid overdose is 0.65% among those who misuse opioids 
(WHO, 2018). In the United States, the opioid overdose death rate of 14.9 deaths per 
100,000 in 2017 represented an increase from the 2016 rate of 13.3 and the 2015 rate of 
10.4 and was an indication of the progression of the opioid misuse problem (Scholl et al., 
2019; Seth et al., 2018). Almost 1% of the U.S. population ages 12 years and older has an 
opioid use disorder (HHS, SAMHSA, 2018). In 2017, over 11 million individuals 
acknowledged using opioids that were not prescribed for them (HHS, SAMHSA, 2018). 
From an economic perspective, opioid misuse and its consequences can be a 
considerable burden. Prescription opioid misuse costs the United States $78.5 billion 
annually in health care, substance use treatment, and criminal proceeding expenditures 
(Florence, Luo, Xu, & Zhou, 2016). In a comparison between opioid abusers and 
nonabusers, Kirson et al. (2017) found that abusers cost taxpayers an average of $14,810 
per patient in incremental health care expenditures each year. Included in the total cost 
were the costs for inpatient, outpatient, emergency department, and rehabilitation facility 
treatment (Kirson et al., 2017). The cost represented a cumulative amount, meaning the 
expenditures accrued up to and after the initial diagnosis of opioid abuse, dependence, or 
overdose (Kirson et al., 2017). Approximately 6 months before the diagnosis of abuse, 
the health care incremental cost for abusers was $3,084, and within 6 months after the 
diagnosis, it was $11,726 (Kirson et al., 2017). The cost began increasing rapidly about 5 
months before the diagnosis of abuse and was attributed to treatment for alcohol abuse 
and nonopioid drug dependence (Kirson et al., 2017). 
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Naloxone is valuable in preventing opioid-related deaths, but little research has 
been conducted to determine whether the ease of access to the medication is associated 
with opioid misuse, specifically repeat opioid overdose. Only one study that addressed 
the impact of the accessibility of the medication on repeat opioid overdose was found 
during the literature review. The study, which is discussed in detail in Chapter 2, was 
qualitative in design and focused on a small sample. Therefore, I concluded there was a 
gap in the research addressing the impact of naloxone’s accessibility on opioid use 
behavior, particularly from a quantitative perspective. The current study may help to fill 
this gap through the quantitative examination of the relationship between opioid overdose 
demographics, naloxone accessibility, and repeat opioid overdose. 
Purpose of the Study 
The purpose of this quantitative, correlational study was to determine the 
relationship between demographics, naloxone accessibility, and repeat opioid overdose in 
a Tennessee county. In doing so, five independent variables (age, gender, race, naloxone 
doses administered by professional first responders, and distribution of naloxone rescue 
kits) and one dependent variable (repeat opioid overdose) were examined. Each of the 
variables is discussed in-depth in Chapter 2. 
Research Questions and Hypotheses 
Research Question 1: What is the association between age and repeat opioid 
overdose? 




Ha1: There is a statistically significant association between age and repeat opioid 
overdose. 
Research Question 2: What is the association between gender and repeat opioid 
overdose? 
H02: There is no statistically significant association between gender and repeat 
opioid overdose. 
Ha2: There is a statistically significant association between gender and repeat 
opioid overdose. 
Research Question 3: What is the association between race and repeat opioid 
overdose? 
H03: There is no statistically significant association between race and repeat 
opioid overdose. 
Ha3: There is a statistically significant association between race and repeat opioid 
overdose. 
Research Question 4: What is the association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose? 
H04: There is no statistically significant association between the naloxone dose 




Ha4: There is a statistically significant association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose. 
Research Question 5: What is the association between the distribution of naloxone 
rescue kits and repeat opioid overdose? 
H05: There is no statistically significant association between the distribution of 
naloxone rescue kits and repeat opioid overdose. 
Ha5: There is a statistically significant association between the distribution of 
naloxone rescue kits and repeat opioid overdose. 
Theoretical Framework 
The diffusion of innovations, popularized by Rogers in 1962, served as the 
theoretical foundation for this study. Subjective information about a new idea is often 
communicated among members of a social group (Rogers, 2003). The diffusion of 
innovations focuses on how, why, and how quickly the subjective information associated 
with the idea is spread—or diffused—among individuals within the social group over 
time (Rogers, 2003). Such focus renders the theory useful in analyzing changes in human 
behavior (Rogers, 2003). 
The four elements on which the diffusion of innovations is premised are the 
innovation, a communication system, time, and a social system composed of individuals, 
groups, or organizations (Rogers, 2002, 2003). An innovation, as discussed by Rogers 
(2002, 2003), is a physical item, idea, or way of doing things perceived by a person or 
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people as something new. Diffusion is the process by which the innovation is perceived 
and communicated over time among a population or social system (Rogers, 2002, 2003). 
The diffusion of innovations posits that the adoption of an innovation is a process 
that typically follows predictable, ordered stages over time (Rogers, 2002, 2003). The 
stages include awareness (learning about or being exposed to the innovation), persuasion 
(forming an opinion—whether positive or negative—about the innovation), decision 
(choosing to accept or reject the innovation), implementation (practicing the innovation), 
and confirmation (seeking validation about the selected innovation decision and deciding 
whether to continue using the innovation; Rogers, 2002, 2003). The increased access to 
and use of naloxone over time may be representative of the stages. 
The stages of adoption of naloxone were evident in many studies. For example, 
Heavey, Chang, et al. (2018) reported that there was naloxone awareness among some at-
risk populations. Cash et al. (2018) demonstrated that naloxone use by EMS professionals 
in opioid overdose rescues was increasing. According to Wheeler, Jones, Gilbert, and 
Davidson (2015), the number of community organizations that advocated and distributed 
naloxone rescue kits was increasing as well. 
Regarding the four elements of the diffusion process, the innovation is naloxone, 
the communication system includes venues such as public health notices from the CDC 
and U. S. Surgeon General that provide the public information about naloxone, time is 
the extent and acceptance of naloxone use, and the social system is the group of 
individuals and organizations (i.e., U. S. Surgeon General, CDC, President, policy 
makers, health and public health professionals, community activists, and members of the 
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public) working to minimize opioid use disorder and mortality. Another component of 
the diffusion of innovations that is often disregarded is understanding what consequences 
are associated with the adoption of the innovation (Rogers, 2003). Because this study 
focused on the progression of naloxone accessibility and how this accessibility relates to 
repeat opioid overdose over a period of time, the choice of the diffusion of innovations as 
a theoretical basis was appropriate to answer the research questions and to address the 
hypotheses. Further details regarding the theory and its applicability are included in 
Chapter 2. 
Nature of the Study 
The nature of this study was quantitative with a correlational, cross-sectional 
design. A quantitative approach includes numerical data that can be analyzed with 
statistical tests to generalize the findings (Creswell, 2014). The correlational design is a 
nonexperimental design used to describe and measure the relationship between two or 
more variables (Creswell, 2014). Creswell (2014) discussed that quantitative data 
collection methods were either longitudinal, in which data about study participants are 
collected over time, or cross-sectional, in which data are collected at one point in time. 
Numerical data collected on the variables in the current study represented a single point 
in time, which made the cross-sectional design appropriate. Because the objective of the 
study was to determine whether relationships existed between the dependent and 
independent variables, the quantitative, correlational approach was appropriate. 
The secondary data used in the study were obtained from a county’s EMS and a 
community-based program that provides opioid overdose training and naloxone kits to 
20 
 
community members. Permission to use data from the organizations was obtained 
through data use agreements, which are included in the Appendix. The organizations de-
identified their data before providing the data sets for this study. 
There were five independent (or predictor) variables in this study: age, gender, 
race, the naloxone dose administered by professional first responders, and the distribution 
of naloxone rescue kits. Age, gender, and race were considered covariates and were 
analyzed as independent variables. Repeat opioid overdose was the only dependent (or 
outcome) variable in the study. Logistic regression was used to assess the relationships 
between age, gender, race, administered naloxone dose, and repeat opioid overdose 
during a specific time frame. Poisson regression was used to examine the relationship 
between distributed naloxone rescue kits and repeat opioid overdose during the same time 
frame. The operationalization of the variables and the rationale for selecting the statistical 
tests are described in Chapter 3. 
Definitions 
The terms used in this study were defined or clarified as follows: 
Emergency Medical Services personnel: Health care professionals who, under 
medical oversight, are trained to provide medical care and transportation in prehospital 
settings and out-of-hospital settings (National Highway Traffic Safety Administration, 
2019). The professionals, in order of their licensure levels, include the emergency 
medical responder, emergency medical technician, advanced medical emergency 
technician, and paramedic (National Highway Traffic Safety Administration, 2019). 
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Index opioid overdose: The first nonfatal opioid overdose experienced by an 
individual (Olfson, Wall, Wang, Crystal, & Blanco, 2018). 
Naloxone access: The possession of naloxone or the ability to readily obtain it 
(Heavey, Chang, et al., 2018). 
Naloxone administration event: The administration of at least one dose of 
naloxone while providing rescue care to an opioid overdose patient (Cash et al., 2018). 
Naloxone rescue kit: An emergency kit used by laypersons to administer naloxone 
to reverse an opioid overdose (Panther, Bray, & White, 2017). There are various types of 
kits, but typically a kit consists of two doses of a 1-mg/mL vial of injectable naloxone, a 
nasal atomizer, a rescue breather, and instructions (Panther et al., 2017). Currently, 
Narcan® Nasal Spray is the rescue kit that is broadly marketed and contains a single 
intranasal spray of 2 mg or 4 mg with instructions (ADAPT Pharma, n.d.). 
Nonfatal opioid overdose: The resuscitation with naloxone of a patient from an 
opioid overdose in which the patient survives at least 1 day following the resuscitation 
(Ray, Lowder, Kivisto, Phalen, & Gil, 2018). 
Opioid: Pain-relieving drugs that are categorized as natural, semisynthetic, or 
synthetic. Natural opioids—also known as opiates—are derivatives of opium poppy and 
include such drugs as codeine and morphine. Semisynthetic opioids include prescription 
drugs such as hydrocodone and oxycodone as well as heroin, an illicit drug. Fentanyl and 




Opioid misuse: The use of heroin or nonmedical use of prescription pain 
medication (McClellan et al., 2018). 
Opioid overdose: The accidental ingestion or administration of an opioid drug that 
causes decreased mental status and/or respiratory depression and requires the 
administration of naloxone, and the patient survives at least 1 day (Samuels et al., 2018). 
Opioid use disorder: The continual use of opioids, notwithstanding the adverse 
consequences, causing significant impairment or distress and manifesting as mental, 
physical, and social problems or increased mortality (Blanco & Volkow, 2019). 
Repeat opioid overdose: The first nonfatal or fatal opioid overdose occurring 
more than 1 day after the first overdose treatment with naloxone (Olfson et al., 2018). 
Take-home naloxone: An intervention that makes naloxone available to 
nonmedically trained individuals to administer to those experiencing an opioid overdose 
(Farrugia et al., 2019). 
Assumptions 
Several assumptions were associated with this study, including one regarding the 
use of secondary data. There was an assumption that the data sets obtained from the 
county’s EMS and the community-based naloxone program were accurate. Both data sets 
contained information about the variables assessed in this study. An accurate measure of 
the variables was important to the accuracy of the results. 
The administration of naloxone by the professional emergency first responders 
was assumed to have been an indication of an opioid overdose. The first responders could 
have administered naloxone to a patient suspected of experiencing an overdose, but the 
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patient’s condition was not confirmed to be an opioid overdose (see Lindstrom et al., 
2015). Such a scenario could have positively skewed the repeat opioid overdose events. 
Such an assumption was likely more of a concern among the LEOs than the EMS 
personnel, as LEOs do not have the same level of training and medical expertise as EMS 
personnel in accurately recognizing an opioid-involved overdose (Rando, Broering, 
Olson, Marco, & Evans, 2015). 
Another assumption regarding the study was that the naloxone administrations by 
the professional emergency first responders were an appropriate proxy measure of the 
county’s public health issue of repeat opioid overdose. Ray et al. (2018) used the same 
approach in their study to examine mortality associated with nonfatal overdoses. Ray et 
al. concluded that the naloxone administrations were suitable proxy data for assessing 
repeat opioid overdose. In the current study, this assumption was necessary because the 
EMS data were the only available measure of the variable of repeat opioid overdose. 
Finally, the individuals who were administered naloxone by the professional first 
responders were assumed to be residents of the county, and the naloxone rescue kits 
distributed through the community-based program were assumed to have been for use 
solely by individuals who resided in the county. 
Scope and Delimitations 
The intent of this study was to determine whether relationships existed between 
demographics, naloxone accessibility, and repeat opioid overdose. The relationships were 
assessed using secondary data collected on a county in Tennessee. The data were 
collected from two sources: the reports of professional first responders who responded to 
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emergency calls regarding a potential opioid overdose and data collected through a 
community-based naloxone program. The target population included anyone in the 
county who was treated with naloxone by a professional first responder during an opioid 
overdose emergency. There were no other delimitations regarding the target population. 
Internal validity refers to the degree of assurance that conclusions about the 
dependent variable are attributed to the independent variables rather than some other 
alternative explanation (Babbie, 2017). The measures of the naloxone dose administered 
by professional first responders and the distribution of naloxone rescue kits were the two 
main independent variables tested for a relationship with repeat opioid overdose. Because 
the literature indicated that the variables of age, gender, and race were risk factors of 
opioid overdose, these variables were treated as potential confounders, which meant they 
could have influenced the outcome variable and threatened the internal validity of the 
study. These demographics were included as independent variables to preclude potential 
confounding and to improve the study’s internal validity. 
The ability to generalize the results that are based on a sample of a population to 
the general population refers to the study’s external validity (Babbie, 2017). In this study, 
the focus was a sample population from a county in Tennessee. Opioid overdose is a 
public health problem in the county. The state has one of the highest opioid-prescribing 
rates in the United States and a rate of opioid overdose deaths that is higher than that of 
the national average (HHS, NIH, NIDA, n.d.-b). Restricting the data collection and 





The lack of access to patients’ medical history of substance abuse and related 
information was a limitation of this study. I relied on data from the professional 
emergency first responders for the measure of repeat opioid overdose. Emergency 
department data that involved individuals who were not transported via EMS were not 
included in the study. Also, resuscitations that might have occurred in residences were 
not included, as these data may never be quantified unless information regarding the 
overdose and resuscitated individual is reported to medical professionals. In light of these 
limitations, the measure of repeat opioid overdose could have been understated, which 
could have biased the results. 
The measure of access to naloxone was limited to the distribution of naloxone kits 
through the community-based program and the administrations of naloxone by 
professional first responders. There are other venues within the county that contribute to 
the accessibility of naloxone, such as local pharmacies, emergency departments, and 
other community-based naloxone distribution programs. Although data from these other 
sources might have increased the strength of the findings in the study, these data sources 
were not part of the study’s scope. 
Another limitation of this study included the correlational design. This design 
precludes the determination of causality. In other words, the design does not allow 
researchers to conclude that the change in one variable was caused by another variable 
(Asamoah, 2014). Because correlational research is useful in determining whether an 
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association exists between variables that occur naturally (Asamoah, 2014), the limitation 
was an acceptable trade-off to achieve the purpose of the study. 
Misclassification bias was also a limitation of this study. As a type of information 
bias that can affect a study’s validity, misclassification bias refers to the accurate 
categorization of observational measurements (Althubaiti, 2016). Professional first 
responders could have incorrectly classified an emergency rescue as an opioid overdose 
when the overdose did not involve an opioid. Such a misclassification could have skewed 
the relationship estimates between the study’s variables (see Althubaiti, 2016). Ensuring 
the thoroughness of the data collection procedures and definitions of the variables can 
help minimize misclassification bias (Szklo & Nieto, 2014). The use of adequately 
defined variables and the reliance on the robustness of the professional first responders’ 
procedures for recording data were measures implemented in this study to mitigate the 
bias. 
Significance 
The expansion of public access to naloxone has improved with the 
implementation of naloxone access laws (Xu, Davis, Cruz, & Lurie, 2018). Such broad-
scale access, however, has been criticized by some who consider it a barrier that 
precludes the cessation of opioid abuse (Rudski, 2016). Some contend that opioid abusers 
will continue or increase their risky use behaviors if naloxone is available to revive them 
if they overdose (Rudski, 2016). Little evidence exists that confirms or refutes the claim. 
Also, there has been little research, especially of a quantitative nature, conducted to 
determine whether the efforts to expand the general public’s access to naloxone have had 
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unintended consequences (i.e., increased overdoses or repeat overdoses). The results of 
the current study may help to advance that knowledge. 
The use of local-level data is important in developing community prevention 
programs (Madah, Clausen, Myrmel, Brattebø, & Lobmaier, 2017). The current study, 
which included use of local data, may be useful to the respective local community. Public 
health practitioners may use the findings to gauge the prevalence of repeat opioid 
overdose and design prevention and intervention programs. The study addressed 
naloxone access policies and legislation that clinicians and pharmacists may use for 
awareness. The data provided by the county’s EMS were valuable in studying naloxone 
accessibility and repeat opioid overdose. The first responder professionals may use the 
results to evaluate the effectiveness of their efforts in saving lives. Finally, educators and 
the local media, partnered with public health practitioners, may use findings from this 
study to educate the community about opioid overdose and naloxone. 
The current opioid overdose mortality statistics are alarming, yet they represent 
only part of the complex, enduring opioid epidemic. According to the WHO (2018), 
nonfatal overdoses occur in approximately 45% of opioid users. Applying the percentage 
to the current estimate of 2.1 million people in the United States who suffer from opioid 
use disorder (Scholl et al., 2019) suggests that there may be as many as 945,000 nonfatal 
opioid overdoses annually in the United States. The importance of the phenomenon is 
that nonfatal overdose is a risk factor for repeat opioid overdose, which increases the 
potential for opioid overdose mortality (Olfson et al., 2018; Ray et al., 2018). From a 
social change perspective, this study provided evidence about the public health problem 
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of repeat opioid overdose, and the findings may be used to reduce the morbidity and 
mortality associated with the opioid crisis. 
Summary 
Opioid overdose is a formidable worldwide public health issue. The United 
States, which has been impacted heavily by the problem since the 1990s, recently 
elevated to the problem to the level of a national public health emergency (Seth et al., 
2018; The White House, n.d.). Approximately 47,600 American deaths are attributable to 
opioid overdose each year (Scholl et al., 2019). Laws and policies have been, and 
continue to be, implemented to address the problem. Ensuring that the public has access 
to naloxone, which is a medication that reverses the effects of an opioid overdose, is one 
of the objectives of the laws and policies. Research on the effectiveness of naloxone 
indicated that the medication is effective in treating opioid overdose (Chou et al., 2017). 
However, little is known about the impact of broad-scale accessibility of naloxone on 
opioid use behavior. The current study was conducted to fill the gap in knowledge and in 
the literature. The in-depth literature review, which was conducted to identify the gap, is 
presented in Chapter 2. The strategy used to conduct the literature review, the theoretical 
basis that guided the review, and a discussion of the variables assessed in this study are 
also presented in Chapter 2. 
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Chapter 2: Literature Review 
The opioid epidemic continues to claim lives worldwide. The purpose of this 
study was to examine the relationship between demographics, naloxone accessibility, and 
repeat opioid overdose. In this chapter, I present the strategy of conducting my literature 
review followed by a discussion of the theoretical framework that I used to guide my 
study. Next, I discuss prominent topics associated with the variables in my research 
questions that surfaced in my in-depth literature review. The topics include repeat opioid 
overdose, the demographics of opioid overdose, naloxone dose, the role of professional 
first responders in administering naloxone during opioid overdose emergencies, and the 
venues associated with the distribution of naloxone. Finally, I discuss opposing 
perspectives regarding the expanded access to naloxone and the gap that I observed in the 
literature. I conclude with a summary. 
Literature Search Strategy 
Sources for this literature review were retrieved from electronic databases 
available through the Walden University library and Google Scholar. Additionally, 
printed book literature was also used. The databases included MEDLINE, CINAHL Plus, 
ProQuest Central, PubMed, SAGE Journals, PsycINFO, ScienceDirect, and the National 
Center for Biotechnology Information. The key terms included in the search were 
naloxone, Narcan, opioid, overdose, recidivism, nonfatal overdose, and repeat OR 
recurrent overdose. The inclusion criteria were articles that were published in English, 
available in full-text academic journals that were peer-reviewed, published within the 
past 5 years (2015–2019), and had an available abstract. Articles that were more than 5 
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years old were included if they provided a historical perspective to the current research. 
Studies were excluded if they did not meet the inclusion criteria. Additionally, articles 
appearing as reviews, case reports, commentaries, opinions, and debates were excluded. 
The titles and abstracts of the remaining articles were reviewed for relevance to this 
study. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines discussed by Moher, Liberati, Tetzlaff, and Altman (2010) were 





Figure 2. Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) study selection process. 
 
Theoretical Foundation 
The diffusion of innovations served as the theoretical framework of this study. 
Although discussed initially in historical literature by Tarde, a French sociologist, the 
theory became popular through the Diffusion of Innovations textbook written by Rogers 
in 1962 (Kaminski, 2011). The diffusion of innovations theory is beneficial in the 
understanding of behavioral change among humans (Rogers, 2003). The theory’s 
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applicability is useful in improving programs aimed at social change (Rogers, 2003). 
Rogers (2003) discussed that an understanding of the characteristics of the innovation and 
the potential adopters is necessary when assessing the viability of the innovation’s 
diffusion. 
Innovation Characteristics 
According to the diffusion of innovations theory, some innovations are diffused 
faster and more pervasively than others. There are five characteristics of an innovation 
that help to explain its rate and extent of adoption: relative advantage, compatibility, 
observability, complexity, and trialability (Rogers, 2002, 2003). Each of these 
characteristics is based on the perception of the individual. 
Relative advantage refers to the individual’s perception of the innovation, 
specifically whether the innovation is more advantageous to the individual than the idea 
or object it replaces (Rogers, 2002, 2003). Innovations with greater relative advantage 
tend to be adopted at a higher rate (Rogers, 2003). Comparability refers to the perception 
about whether the innovation is consistent with the individual’s values and normative 
beliefs (Rogers, 2002, 2003). An innovation that aligns with the individual’s beliefs and 
values is adopted with less resistance than one that requires the individual to change their 
belief/value system (Rogers, 2003). Observability is the degree to which the innovation’s 
benefits or outcomes are evident to the potential adopter (Rogers, 2002, 2003). Seeing the 
results of an innovation, whether positive or negative, generates discussion by the adopter 




The characteristic of complexity, which refers to the perception about the ease of 
use or understanding of the innovation, is straightforward (Rogers, 2002, 2003). Simple 
ideas are easier to understand and, therefore, are adopted quicker than those based on 
complex knowledge or require the development of new skills (Rogers, 2003). Trialability 
is the extent to which the innovation can be tried before committing to adopt it fully 
(Rogers, 2002, 2003). Trialability helps the individual determine whether the innovation 
is a good fit. An innovation that lends itself to a trial run has a better chance of being 
adopted (Rogers, 2003). 
Characteristics of Innovation Adopters 
The diffusion of innovations theory addresses characteristics about the people of a 
social system as they evaluate an innovation for adoptability. The first 2.5% of people 
within the system to adopt an innovation are identified as innovators (Rogers, 2002, 
2003). These individuals are knowledge seekers who are not afraid of the uncertainty 
regarding the innovation, nor do they bind themselves by adhering to social norms 
(Rogers, 2002, 2003). The next group is the early adopters who constitute 13.5% of the 
social system (Rogers, 2002, 2003). As visionaries and trendsetters, early adopters are 
well connected socially and are viewed as role models (Kaminski, 2011; Rogers, 2003). 
Early adopters are highly respected within the social system and are capable of 
influencing opinions and norms (Rogers, 2003). With their knowledge, their respected 
opinions, and their ability to influence large peer groups, the innovators and early 
adopters are valuable in launching an effective and successful innovation (Rogers, 2003). 
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The early majority is the next category in the diffusion process, followed by the 
late majority. Each of these two categories constitutes 34% of the social system (Rogers, 
2002, 2003). Those in the early majority category are pragmatic and prefer proof—
usually from the innovators and early adopters—that the innovation is worthwhile and 
reliable (Kaminski, 2011; Rogers, 2003). The early majority individuals have frequent 
interactions with their peers, and their opinions are valued by their peers (Kaminski, 
2011; Rogers, 2003). The late majority members, on the other hand, are conservative 
(Kaminski, 2011; Rogers, 2003). These individuals tend to be skeptical about the 
innovation and will adopt it only if it is an economic necessity and only if it is endorsed 
by a trusted peer (Kaminski, 2011; Rogers, 2003). 
The last category is the laggards, representing 16% of the social system (Rogers, 
2002, 2003). The laggards are the most skeptical among the categories and prefer 
traditionalism over new things, ideas, or behaviors (Kaminski, 2011; Rogers, 2003). 
Because the laggards are often isolated from those in other categories, they have little 
knowledge about the innovation and, therefore, are the last ones to adopt it (Kaminski, 
2011; Rogers, 2003). As late adopters in the diffusion of innovations process, the early 
majority, the late majority, and the laggards share the behavior of adopting the innovation 
only if it has been adopted and endorsed by their close peers (Rogers, 2002, 2003). 
Applications of the Diffusion of Innovations Theory 
Myriad research studies incorporating the diffusion of innovations theory have 
been conducted in various disciplines. Economics, organization, social psychology, 
sociology, anthropology, and political science are social science disciplines in which the 
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theory has been used as a framework of research projects (Rogers, 2003). Very few 
articles in the literature included discussions on the theory as it relates to naloxone 
accessibility and repeat opioid overdose. 
Bowles and Lankenau (2019) used the diffusion of innovations theory in their 
qualitative study of 30 individuals who reported injecting heroin. The innovation was an 
opioid overdose prevention program (OOPP) operated by a harm reduction facility. 
OOPPs, sometimes referred to as opioid overdose prevention and response (OOPR) 
programs, overdose prevention and naloxone distribution (OPND) programs, or opioid 
overdose education and community naloxone distribution (OEND) programs, are venues 
where laypersons can obtain naloxone rescue kits and opioid overdose prevention 
training. The training helps individuals to identify and respond to an overdose and to 
administer naloxone if necessary (Bowles & Lankenau, 2019; Heavey, Chang, et al., 
2018; Koester, Mueller, Raville, Langegger, & Binswanger, 2017; Lambdin, Zibbell, 
Wheeler, & Kral, 2018; Prabhu et al., 2017; Sherman et al., 2009). 
Bowles and Lankenau (2019) applied the diffusion of innovations theory to 
determine the effectiveness of an OOPP in reaching a community of people in 
Philadelphia who inject drugs. Although subject to social desirability bias and recall bias, 
the study indicated that the participants were receptive to the OOPP when the innovation 
was championed by workers within the harm reduction facility (Bowles & Lankenau, 
2019). The influence of the harm reduction workers as champions of the innovation 
underscores a strategy discussed by Rogers (2002). Champions who are skilled in 
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persuading and negotiating with people can be valuable in attracting potential adopters, 
thereby expediting the innovation’s rate of diffusion (Rogers, 2002, 2003). 
The diffusion of innovations theory was also employed by Sherman et al. (2009) 
who conducted a qualitative study to examine the diffusion of information by 25 
participants who attended an OPND program. Sherman et al. sought to understand the 
nature of the information that was diffused throughout a community of injection drug 
users in Baltimore, Maryland. Sherman et al. found that 90% of the participants 
experienced at least one overdose (with a median of two overdoses) and that 20% of the 
participants died from an overdose. 
Sherman et al. (2009) found that the OPND program was effective in training 
people to recognize and respond to an overdose and in diffusing program information 
within the community. The participants who attended the program were more likely to 
promote the program to their peers when they administered naloxone during an overdose 
that they witnessed or when they discussed their own overdose experiences. Sherman et 
al. concluded that information from the program diffused faster when the participants had 
personal experiences to share than it did when the participants had only on the 
information they learned in the training. The participants in Sherman et al.’s study were 
likely late majority adopters of the OPND program (i.e., the innovation), as they might 
have been skeptical about the program or might have required proof that it was helpful. 
Theory Relevance to Current Study 
The surge of opioid-related deaths that began in the late 1990s gave rise to general 
public awareness of naloxone (Humphreys, 2015). There is a dearth of literature in which 
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the diffusion of innovations theory served as a framework for studies involving naloxone. 
Only two such studies were found, and they were qualitative in design. The theory was 
selected as a basis for this current study because of its temporal aspect. The use of 
naloxone has progressed from being administered solely by medically trained 
professionals to being administered by peers and family members of people who misuse 
opioids (McDonald, Campbell, & Strang, 2017). The aim of this current study was to 
examine the distribution of naloxone during a specific time frame to determine whether it 
correlated with repeat opioid overdoses during the same time frame. According to the 
diffusion of innovations theory, time is one of the four key elements associated with the 
diffusion of a new idea; the innovation, channels of communication, and social system 
are the other three elements (Rogers, 2002, 2003). Because the focus of this study 
entailed the examination of the effect of naloxone’s accessibility on repeat opioid 
overdose during a period of time, the theoretical framework was appropriate. 
Repeat Opioid Overdose 
Repeat opioid overdose is an insidious public health problem that is a component 
of the current opioid epidemic. In 2016, of those who died from an overdose involving 
illicit, prescription, or a combination of illicit and prescription drugs, 15.1%, 13.5%, and 
9.3%, respectively, had experienced at least one previous opioid-related overdose 
(Mattson et al., 2018). Not all users of opioids embrace the notion of abstaining from 
opioids even when they experience an overdose (Keane et al., 2018). Some studies 
suggest that repeat opioid overdose is a growing public health problem. Lasher, Rhodes, 
and Viner-Brown (2019) conducted a study in Rhode Island to quantify EMS dispatches 
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involving opioid overdose. Lasher et al. (2019) found that 13.2% of the 1,288 patients 
treated by EMS first responders for opioid overdose in 2018 had experienced between 
one and nine repeat overdoses within the past year and that 2.6% of the patients had 
experienced two or more prior overdoses. Klebacher et al. (2017) found that 27.2% of 
2,166 patients treated for opioid overdose by EMS first responders between 2014 and 
2016 in New Jersey had experienced a previous overdose. 
Dahlem et al. (2017), evaluated the naloxone training provided to 114 LEOs in a 
Michigan county and found that two of the 32 overdoses that required the administration 
naloxone were repeat overdoses. Warfield et al. (2019), found that 18.2% of the 833 
patients admitted to a hospital system in West Virginia between 2008 and 2016 for opioid 
overdose experienced at least one repeat opioid overdose within the past year and that the 
repeat overdoses increased annually on average by 13%. Ray et al. (2018) examined 
opioid overdose mortality outcomes in an Indiana county and found that 13.4% of the 
4,726 patients revived with naloxone by EMS first responders between 2011 and 2016 
had experienced between one and 12 repeat opioid overdoses. Such evidence seems to 
indicate that the problem is not negligible or isolated. 
The studies conducted by Lasher et al. (2019), Klebacher et al. (2017), Dahlem et 
al. (2017), and Warfield et al. (2019) addressed the problem of repeat opioid overdose at 
the county and state levels. Olfson et al. (2018) examined the problem from a national-
level perspective. Olfson et al. conducted a retrospective cohort study with data collected 
from 45 states to examine risk factors of repeat opioid overdose occurring within the first 
year of an index opioid overdose. The sample consisted of 75,556 Medicaid patients 
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between the ages of 18 and 64. Within the first year following the index overdose, 18.9% 
of the patients had a repeat opioid overdose, and 1% had a repeat opioid overdose that 
was fatal (Olfson et al., 2018). The rate of repeat opioid overdose in the cohort was 295.0 
per 1,000 person-years (Olfson et al., 2018). The hazard ratio of repeat opioid overdose 
among those patients who overdosed on heroin was higher than the hazard ratio of those 
patients who overdosed on prescription opioids (Olfson et al., 2018). Those patients who 
took prescription opioids within 180 days of their index opioid overdose had a higher 
hazard ratio of repeat opioid overdose than those patients who did not (Olfson et al., 
2018). Although Olfson et al. used data that were more than 10 years old, the findings 
support the notion that a nonfatal opioid overdose often results in a repeat opioid 
overdose within 1 year. 
Another retrospective cohort study in which national-level data were used was 
conducted by Larochelle, Liebschutz, Zhang, Ross-Degnan, and Wharam (2016). 
Larochelle et al. (2016) examined the opioid prescriptions of 2,848 patients who 
experienced an index opioid overdose to determine whether there was a relationship 
between the prescription dosage and repeat opioid overdose. Larochelle et al. found that 
7% of the patients experienced a repeat opioid overdose and that opioid prescriptions 
continued to be written for patients after their index overdose. The risk of repeat opioid 
overdose was higher among the patients who received prescriptions for higher opioid 
dosages (Larochelle et al., 2016). Although the design of the study by Larochelle et al. 
precluded a causal determination, the results were consistent with the findings from 
40 
 
Olfson et al. (2018). Both studies provided evidence to indicate that individuals who 
experience their first nonfatal opioid overdose are likely to experience a repeat overdose. 
Opioid Overdose Demographics 
Opioid overdose, whether nonfatal or fatal, affects all demographic groups. 
Olfson et al. (2018) analyzed national data from the Centers for Medicare and Medicaid 
Services and found that individuals who experienced a nonfatal opioid overdose were 
predominantly White (71.1%), female (59.2%), and over 34 years of age (70.3%). 
National EMS data examined by Cash et al. (2018) indicated that of the 207,548 rescues 
involving the administration of naloxone by EMS first responders in 2016, 61.3% of the 
patients were male; 72.0%, White; and 21.4%, Black. Among the age groups, those who 
were 25–34 years of age had the largest proportion of naloxone administration events 
with 23.0%, followed by the 45–54 age group with 17.6%, the 35–44 age group with 
16.5%, and the 55–64 age group with 15.7% (Cash et al., 2018). 
A cross-sectional analysis of national data by Scholl et al. (2019) indicated that 
the rate of death from opioid overdose (i.e., all opioids overdose) per 100,000 population 
in 2017 was 20.4 for men and 9.4 for women. The age groups with the highest rates of 
death were those 25–34, 35–44, 45–54, and 55–64, with rates of 29.1, 27.3, 24.1, and 
17.0, respectively (Scholl et al., 2019). The analysis of the age and sex subgroups 
indicated that males and females who were 25–44 years of age had the highest rates of 
death at 40.0 and 16.3, respectively (Scholl et al., 2019). Among the race groups, the 
rates were 19.4 among Whites, 12.9 among Blacks, 6.8 among Hispanics, 15.7 among 
American Indians/Alaska Natives, and 1.6 among Asian/Pacific Islanders (Scholl et al., 
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2019). Scholl et al. compared the 2017 data to the 2016 data and found that the rates of 
death from opioid overdose increased overall within the demographic groups. 
Scholl et al. (2019) found that Whites had a higher rate of opioid overdose 
mortality than that of Blacks and that the rate of opioid overdose mortality was increasing 
among Blacks. The phenomenon was reversed at the beginning of the opioid epidemic. 
The Black population sustained the heavier burden of opioid overdose mortality from the 
late 1970s to the mid-1990s, an era in which opioid-related mortality was driven by 
heroin use (Alexander, Kiang, & Barbieri, 2018). From the mid-1990s to 2010, the racial 
gradient shifted such that the White population had the greatest burden of opioid 
overdose mortality (Alexander et al., 2018). The fatalities during this period were 
advanced by the use of licit opioid pain relievers (Alexander et al., 2018). Since 2010, the 
rate of opioid-related deaths continues to be highest among Whites than among any other 
racial group but is increasing in all groups (Alexander et al., 2018). Heroin and synthetic 
opioids (i.e., fentanyl and its analogs) are the current drivers of opioid-related mortality 
(Alexander et al., 2018). The annual increase in fatality rates involving heroin is 31% 
among Whites and 34% among Blacks (Alexander et al., 2018). The heroin statistics may 
be alarming, but they pale to those involving synthetic opioids, which are responsible for 
mortality rates that are increasing among Whites and Blacks annually at 79% and 107%, 
respectively (Alexander et al., 2018). 
Naloxone Dose 
The dose of naloxone necessary to achieve resuscitation from an opioid overdose 
depends on the formulation of the pharmaceutical. The initial recommended dose is 0.4–2 
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milligrams (mg) for intravenous injections; 2 mg or 4 mg (depending on how the 
pharmaceutical is supplied) per single spray in each nostril for Narcan® nasal spray, and 
2 mg intramuscularly or subcutaneously for Evzio® (HHS, NIH, NLM, n.d.-b). Naloxone 
has an onset of action of 2–3 minutes and a half-life in the body of 1–1.5 hours (Handal 
et al., 1983; WHO, 2014). The half-life (i.e., plasma half-life) of naloxone is shorter than 
that of many opioids, including OxyContin®, fentanyl, morphine, codeine and 
methadone (Willman, Liss, Schwarz, & Mullins, 2017; WHO, 2014). Overdoses 
involving opioids with longer half-lives may require additional doses of naloxone to 
prevent opioid rebound toxicity, which is the return of opioid overdose symptoms after 
the initial overdose reversal (WHO, 2014). Regaining consciousness and breathing 
normally are indications that the administered naloxone was effective in reversing the 
overdose (Lasher et al., 2019). If the signs of recovery are not observed, the dose can be 
repeated every 2 to 3 minutes as needed (HHS, NIH, NLM, n.d.-b). 
Different doses and multiple administrations of the doses are often necessary 
during the rescue of opioid overdose patients. Lasher et al. (2019) observed that of the 
1,006 doses of naloxone administered by EMS first responders between 2016 and 2018 in 
Rhode Island, 44.3% of the administrations were intravenous deliveries; 46.5%, 
intranasal; and 7.3%, intramuscular. Lasher et al. found that 26.4% of the patients 
required multiple administrations of naloxone and that the mean total dose of naloxone 
administered was 2.7 mg. Klebacher et al. (2017) found that 91% of the 2,166 study 
participants required one 2-mg dose of intranasal naloxone, 9% required two doses, and 
2.4% required three doses. Klebacher et al. also found that of the patients who received 
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intravenous doses of naloxone, 51% received 2 mg, 26% received 0.4 mg, and 21% 
received 1 mg. Neither Lasher et al. nor Klebacher et al. included information about the 
type of opioid that was involved in the overdoses in their studies. 
Information collected on naloxone doses during opioid overdose rescues can 
improve understanding of the opioid epidemic. Heavey, Delmerico, et al. (2018) found 
that LEOs and firefighters administered an average of 1.76 doses of 2-mg intranasal 
naloxone to 800 overdose victims and that the first responders noted the presence of 
heroin at 79.1% of the overdose scenes. Although the collection of data about the 
involved opioid was not within the scope of the studies by Lasher et al. (2019) and 
Klebacher et al. (2017), such information might have provided valuable insight regarding 
the efficacy of the naloxone doses. According to Faul et al. (2017), multiple 
administrations of naloxone doses during an attempt to resuscitate an overdose victim 
may be a proxy for gauging the potency of the ingested opioid. 
Professional First Responders 
EMS personnel and LEOs are professional emergency first responders uniquely 
positioned to perform crucial roles in reducing opioid overdose fatality rates. If these 
professionals are contacted in time, they can administer naloxone as a prehospital 
treatment to prevent or reverse an opioid overdose. Policy changes in Massachusetts, 
which broadened the role of many of these first responders, advanced the expansion of 
naloxone access in the state, which reduced opioid overdose emergency response times 
(Davis et al., 2014). Additional studies have since been published that provide evidence 
of the effectiveness of naloxone administrations by EMS and LEO professionals. 
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Emergency Medical Services 
EMS personnel are typically the first medically trained professionals to arrive at 
an overdose scene (Faul et al., 2017). Depending on their level of certification, EMS 
personnel can administer naloxone as part of standard care, revive patients in cardiac 
arrest, and perform procedures such as tracheal intubations when naloxone administration 
attempts by bystanders or other first responders are unable to revive the overdose victim 
(Banta-Green et al., 2017; Cash et al., 2018; Faul et al., 2017; National Highway Traffic 
Safety Administration, 2019). As of 2015, the administration of naloxone was limited to 
EMS personnel with advanced life support training (i.e., paramedics), with only 12 states 
allowing those responders with basic life support training to administer the 
pharmaceutical (Faul et al., 2015). 
Faul et al. (2015) discussed the importance of expanding the use of naloxone to 
include other EMS personnel in helping to reduce opioid-related deaths. The rationale 
focused on the greater likelihood that EMS personnel with basic life support training 
would be the first to arrive at opioid overdose scenes in rural areas (Faul et al., 2015). 
Recent research indicated that as many as 35 states authorized those EMS first responders 
with basic life support training to administer naloxone and that the responders in rural 
areas demonstrated improved knowledge of opioid overdose and naloxone administration 
after training (Zhang, Marchand, Sullivan, Klass, & Wagner, 2018). EMS personnel in 
the United States administer naloxone at the rate of 1,004.4 per 100,000 EMS naloxone 
administration events (Cash et al., 2018). When called to respond to an opioid overdose, 
EMS personnel perform life-saving procedures at the scene, provide overdose victims 
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with referrals to opioid misuse treatment programs, and stabilize critical patients while 
transporting them for additional care at emergency departments. 
Law Enforcement Officers 
LEOs often arrive at the scene of an overdose before EMS first responders (Davis 
et al., 2014; Davis et al., 2015). In rural areas, which typically have a higher burden of 
overdose, LEOs who perform routine patrols are often the first to respond to an overdose 
(Faul et al., 2015; Rando et al., 2015; Wagner, Bovet, Haynes, Joshua, & Davidson, 
2016). With adequate naloxone training, LEOs can be key components in the 
multifaceted approach to solve the opioid overdose crisis. 
Rando et al. (2015) conducted a prospective intervention study in an Ohio county 
to determine whether LEOs could administer naloxone to help reduce the county’s opioid 
overdose mortality rate. The intervention was a 2-hour training session in which the 
LEOs practiced performing basic life-saving procedures, identifying potential opioid 
overdose victims, and administering intranasal naloxone (Rando et al., 2015). Rando et 
al. found that the rate of opioid overdose deaths before and after the LEO training was 1.5 
(p < .002) and -4.1 (p < .025) deaths per quarter, respectively, which indicated a decrease 
in the mortality rate. There were few limitations associated with the study, the primary 
one being an issue regarding the LEO’s ability to accurately identify an opioid overdose. 
An accurate identification of an opioid overdose can be problematic even for well-trained 
EMS personnel because depressed respiration—a typical indication of overdose—could 
result from other etiologies or nonopioid drugs ingested by the victim (Williams et al., 
2019). The results observed by Rando et al. indicated a statistically significant decrease 
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in the number of opioid overdose deaths in the county, which was attributed to the 
naloxone administration training provided to the LEOs. 
Whereas Rando et al. (2015) measured the effectiveness of the LEO naloxone 
administration training by the change in opioid overdose mortality rate, other researchers 
have since conducted studies in which they measured the effectiveness through pretest–
posttest training measurements of the LEOs’ knowledge and abilities regarding naloxone 
use. For example, in a pilot program evaluation, Wagner et al. (2016) provided training to 
81 LEOs that involved recognizing and responding to an overdose and administering 
intranasal naloxone. Pretest–posttest training surveys of the 81 LEOs and qualitative 
interviews with four of the LEOs indicated improvements in the knowledge and 
confidence of the LEOs in identifying an opioid overdose and administering naloxone 
(Wagner et al., 2016). The LEOs administered naloxone to 11 overdose victims within 
the first 4 months after training and revived nine of the victims successfully (Wagner et 
al., 2016). The pilot program was a positive indication that LEOs could manage opioid 
overdose situations (Wagner et al., 2016). 
Another study in which the pretest–posttest measurement approach was used was 
conducted by Dahlem et al. (2017). Dahlem et al. evaluated a naloxone training program 
by administering pre-opioid overdose knowledge surveys to 98 LEOs, training the 
officers on opioid overdose and naloxone education, and administering posttest opioid 
overdose knowledge surveys to the officers. The training included information regarding 
the benefits of naloxone, how to recognize an opioid overdose, and how to administer 
intranasal naloxone (Dahlem et al., 2017). The LEOs were instructed on how to link an 
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overdose victim to substance use treatment, and the LEOs listened to a testimony of a 
recovering opioid overdose victim who had been guided to treatment by an LEO (Dahlem 
et al., 2017). The testimony, which was added to address the stigmatization associated 
with active addiction, and the instructions regarding linkage to care were training 
components that were not included in the training program evaluated by Wagner et al. 
(2016). 
Similar to the findings from Wagner et al. (2016), the results from Dahlem et al. 
(2017) indicated statistically significant improvements in all measured knowledge areas 
of the LEOs. Within the first year of completing the training, the LEOs administered 
naloxone to 32 overdose victims, revived 31 of the victims successfully, and linked six of 
the victims to treatment services (Dahlem et al., 2017). As in the study by Wagner et al. 
(2016), the sample size in Dahlem et al.’s study was small, which limited the study’s 
generalizability. Despite the limitation, Dahlem et al.’s study provided evidence that the 
naloxone training approach improved the LEOs’ knowledge of the medication and 
provided the first responders with the skills to reverse an opioid overdose by 
administering the life-saving naloxone. Additionally, the study indicated that LEOs were 
valuable in facilitating the overdose victim’s linkage to treatment (Dahlem et al., 2017). 
Heavey, Delmerico, et al. (2018) used county opioid overdose reports to examine 
the effectiveness of the training that had been provided to LEOs and firefighters on how 
to administer naloxone in opioid overdose situations. The opioid overdose reports had 
been completed by LEOs and firefighters who had completed naloxone training. Heavey, 
Delmerico, et al. found that the officers and firefighters administered naloxone to 800 
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overdose victims during a 2-year period and revived 653 (81.6%) of the victims 
successfully. The training provided to the LEOs and firefighters helped reduce the 
overdose-related deaths in the county (Heavey, Delmerico, et al., 2018). 
Distribution of Naloxone 
National, state, and local public health efforts ensure that the public is 
knowledgeable about naloxone and that those individuals who need the overdose reversal 
medication have access to it. Community-based programs, emergency departments, and 
pharmacies are among the institutions associated with naloxone expansion efforts. 
Community-Based Programs 
Community-based organizations (i.e., homeless shelters, substance abuse 
treatment facilities, health care setting, HIV testing and linkages to care centers, harm 
reduction centers, and health care providers) have provided naloxone through OOPP, 
OOPR, OPND, and OEND programs in the United States since 1996 (Bagley, Forman, 
Ruiz, Cranston, & Walley, 2018; Wheeler, Davidson, Jones, & Irwin, 2012). The 
programs provide support services to individuals with opioid use disorders as well as to 
their family members and friends (Wheeler et al., 2012). Linking individuals who suffer 
from opioid use disorder to treatment centers is a key service provided by the programs 
(Wheeler et al., 2012). In addition to naloxone, training that helps the participants 
understand the risk factors associated with opioid overdose, recognize opioid overdose 
signs, call 911 for medical assistance, and administer naloxone to overdose victims is 
also provided through these programs (Wheeler et al., 2012). The effectiveness of such 
programs has been evaluated in many studies. 
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 The Massachusetts Department of Public Health (MDPH) operates a state OEND 
program that supports community-based organizations in providing opioid overdose 
education and naloxone rescue kits to individuals at risk of overdose and to the family 
members of the individuals (Bagley et al., 2018). Bagley et al. (2018) used data collected 
via the MDPH OEND to study the characteristics of 10,827 family members who 
accessed the naloxone resource between 2008 and 2015. The MDPH OEND program 
reported 4,373 successful opioid overdose reversals during this period, with 860 (20%) of 
the reversals attributed to the quick response of family members (Bagley et al., 2018). 
Although the use of self-report data was a limitation of the study, the large sample size 
enabled an extensive analysis of the characteristics of the families (Bagley et al., 2018). 
Bagley et al. concluded that family members could perform crucial, active roles in 
reducing opioid overdose. Community-based naloxone programs engage family members 
who are willing to learn about opioid overdose and administer naloxone to help save lives 
(Bagley et al., 2018). The family is an important social network component of the 
individuals who are dependent on opioids and should be leveraged by public health 
practitioners in the fight against the opioid epidemic (Bagley et al., 2018). 
Pade, Fehling, Collins, and Martin (2017) examined the impact of an OEND 
program established within a substance use residential treatment facility in Colorado. The 
study participants included 47 opioid-dependent patients from the treatment facility and 
their family members (Pade et al., 2017). Training was provided to the participants, and a 
pretest–posttest training questionnaire was used to assess the family members’ 
knowledge and perception about opioid overdose (Pade et al., 2017). Pade et al. (2017) 
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concluded that the OEND program was implemented successfully within the treatment 
facility and that the family members demonstrated proficiency in recognizing and 
managing an opioid overdose situation. Pade et al. emphasized that OEND programs 
were important as a harm reduction approach and that the caregivers in treatment 
facilities should consider implementing such programs rather than relying solely on an 
abstinence-based care approach. Substance use treatment facilities can incorporate OEND 
programs and leverage them as harm reduction tools to manage high-risk patients and 
empower the family members with the skills and abilities to save lives (Pade et al., 2017). 
Rowe et al. (2015) conducted a study to examine the demographic characteristics 
of the participants who attended the Drug Overdose Prevention Education Project, a 
community-based naloxone program in San Francisco. Identifying the predictors 
associated with the participants’ reporting of naloxone refills and overdose reversals was 
also a focus of the study (Rowe et al., 2015). Training, naloxone, and health services 
were provided through the program to individuals who were likely to experience or 
witness an opioid overdose (Rowe et al., 2015). The program was dynamic in that it was 
used to service high-risk opioid users at needle exchange locations, opioid treatment 
facilities, and pain management clinics (Rowe et al., 2015). High-risk users who resided 
in single-room occupancy hotels were serviced through the program as well (Rowe et al., 
2015). Rowe et al. found that program participants who were White, used illicit opioids, 
and experienced or witnessed an overdose were more likely to obtain naloxone refills. 
The participants who used illicit opioids and experienced or witnessed an overdose were 
more likely to report an overdose reversal (Rowe et al., 2015). The program was effective 
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in reaching high-risk opioid users and in training them to use naloxone to reverse an 
opioid overdose (Rowe et al., 2015). Rowe et al. used self-report data in their study, 
which meant the results were subject to social desirability and recall bias limitations. The 
study provided evidence that community-based naloxone programs could reach high-risk 
populations and educate them on opioid overdose prevention. 
Emergency Departments 
Emergency departments are opportune venues for the provision of naloxone 
education and rescue kits to opioid overdose survivors and to their family and friends. 
Between July 2016 and September 2017, opioids were suspected in 15.7 per 10,000 
overdoses assessed during emergency department visits (Vivolo-Kantor et al., 2018). 
This statistic equated to 142,557 suspected opioid overdoses, all of which represented 
opportunities to provide the patients with take-home naloxone kits, education them on 
opioid overdose, and link them to treatment centers or other needed services. (Vivolo-
Kantor et al., 2018). Taking advantage of such opportunities may help save lives, as a 
repeat opioid overdose or an opioid overdose-related fatality is often the outcome of a 
nonfatal opioid overdose (Olfson et al., 2018). 
 Samuels et al. (2018) conducted a retrospective cohort study to evaluate the 
impact that an emergency department intervention program had on repeat opioid 
overdose, linkage to care timeliness, and opioid overdose mortality. The program was 
called Lifespan Opioid Overdose Prevention, and it was the collaborative initiative of 
several public health organizations in Rhode Island (Samuels et al., 2018). Naloxone, 
opioid overdose education, and a peer recovery coach were provided to the opioid 
52 
 
overdose patients through the program, which was established in two emergency 
departments within the state (Samuels et al., 2018). The role of the peer recovery coach—
who was an individual enrolled for at least two years in addiction treatment—was to 
motivate and navigate the opioid overdose patient to seek substance use treatment 
(Samuels et al., 2018). The sample was composed of 151 opioid overdose patients who 
received treatment from the two emergency departments, and the treatments consisted 
either of usual care, take-home naloxone along with educational materials, or a 
combination of take-home naloxone and a peer recovery coach (Samuels et al., 2018). 
The usual care treatment included stabilizing the patient from the overdose and providing 
the patient with printed information about substance use treatment programs (Samuels et 
al., 2018). 
Samuels et al. (2018) found that the all-cause mortality and the incidence of 
repeat opioid overdose were lowest among the take-home naloxone group, followed 
closely by that of the take-home naloxone plus recovery coach group. Patients in the 
take-home naloxone plus recovery coach group sought linkage to care sooner than the 
patients in the other two treatment groups (Samuels et al., 2018). The study provided 
evidence that the distribution of naloxone kits by emergency departments were associated 
with reductions in the repeat opioid overdose visits to the emergency department, 
reductions in the length of time that an individual chose to seek substance use treatment, 
and reductions in the opioid overdose mortality (Samuels et al., 2018). 
Gunn et al. (2018) conducted a systematic review of the literature to summarize 
the evidence available on the role of emergency departments in the distribution of 
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naloxone. Gunn et al. found that emergency departments were valuable as harm reduction 
mechanisms in the efforts to improve naloxone access and reduce opioid overdose. As 
points of entry for urgent care, emergency departments serve as a venue for educating 
individuals with opioid use disorders who do not have access to other health care 
facilities (Gunn et al., 2018). To be effective in this role, emergency departments require 
support from senior management in overcoming barriers such as the insufficient time to 
train the staff and the lack of staff to distribute naloxone and counsel overdose patients 
(Gunn et al., 2018). 
Papp and Schrock (2017) hypothesized that the provision of naloxone kits by 
emergency departments would reduce repeat opioid overdose as well as opioid-related 
morbidity and mortality. Papp and Schrock conducted a retrospective cohort study of 291 
patients who presented with heroin overdose to an urban emergency department from 
2013 to 2016. Papp and Schrock compared the composite outcomes (i.e., at 3 months and 
at 6 months) of patients who received naloxone kits at discharge to the outcomes of the 
patients who did not and found no significant difference between the groups. Papp and 
Schrock discussed that the small sample was a limitation of the study that could have 
influenced the results. Confounders, though not discussed as limitations by Papp and 
Schrock, might have accounted for the observation of no significant difference between 
the groups. For example, patients who did not receive naloxone kits from the emergency 
department might have enrolled in substance use treatment facilities where the 




The role of pharmacies in the expansion of access to naloxone was emphasized in 
the Comprehensive Addiction and Recovery Act (2016). States were encouraged to 
implement standing orders that would allow pharmacists to supply naloxone to 
individuals needing the medication (Comprehensive Addiction and Recovery Act, 2016). 
Xu et al. (2018) conducted a cross-sectional study to analyze naloxone dispensing based 
on state-level naloxone access legislation. Xu et al. found that such legislation was 
associated with national increases in naloxone dispensed by retail pharmacists. From 
2007 to 2016, naloxone dispensed via prescriptions increased by over 9,800%, with the 
greatest upsurge occurring between 2015 and 2016 (Xu et al., 2018). Similar results were 
observed by Freeman, Hankosky, Lofwall, and Talbert (2018), who used national 
naloxone prescription data to examine the impact of access legislation on the dispensing 
rate of naloxone by states. Freeman et al. (2018) found a nearly eightfold increase in 
dispensed naloxone prescriptions by states from October 2015 through June 2017. 
Freeman et al. attributed the phenomenon to the diffusion of legislation designed to make 
naloxone accessible to the public through the availability of Narcan® and Evzio®. 
Despite the positive influence of naloxone laws on increased prescriptions by 
pharmacies, the expansion of access to pharmacy-provided naloxone has not been as 
progressive in many locations. For example, Freeman et al. (2018) found that while 
dispensing rates were as high as 244 prescriptions per 100,000 persons in states such as 
Virginia, the rates were as low as 2.2 prescriptions per 100,000 in other states such as 
Hawaii. In many communities in North Carolina, naloxone is neither offered nor 
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dispensed by pharmacists (Carpenter et al., 2019). According to Carpenter et al. (2019), 
many community pharmacists who did not offer naloxone indicated they lacked the time 
or adequate training to do so. Some pharmacists also indicated they felt that their patients 
would not comprehend the use of naloxone and, therefore, did not offer the medication 
(Carpenter et al., 2019). The limited expansion of access to naloxone might have been 
isolated to these instances. Regardless, additional efforts by national, state, and local 
policy makers are necessary to ensure universal and consistent implementation of 
pharmacy-based naloxone distribution programs (Bachyrycz, Shrestha, Bleske, Tinker, & 
Bakhireva, 2017). 
Controversy Regarding Broad Distribution of Naloxone 
The effectiveness of naloxone in reversing an opioid overdose may not be a 
controversial topic, but the perceived impact of the medication on the misuse of opioids 
is. Not everyone supports the public health measures of expanding the access of naloxone 
to laypersons. Some opponents of publicly available naloxone believe that increasing 
laypersons’ accessibility to the pharmaceutical may cause an increase in the use of 
opioids (Keane et al., 2018). This conception is premised on risk compensation, which is 
a belief that the provision of naloxone will encourage opioid misuse (Keane et al., 2018). 
In a cross-sectional study of 276 online participants, Rudski (2016) found that 59.1% of 
the participants believed that expanded access to naloxone caused opioid users to 
perceive the medication as a safety net and that it encouraged the opioid users to engage 
in reckless drug use. Additionally, 58.0% of the participants believed that making 
naloxone easy to access by laypersons discouraged the cessation of drug use, 43.8% 
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believed that promoting naloxone represented condoning the use of opioids, and 39.5% 
believed that easy access to naloxone undermined the emphasis on abstaining from opioid 
misuse (Rudski, 2016). 
Negative perceptions regarding easy access to naloxone by laypersons have been 
discussed in some studies. Haug et al. (2016) found that health care providers, 
particularly nurses and emergency medical technicians, often stigmatized their opioid 
overdose patients and maintained the opinion that naloxone did little to reduce opioid 
addiction. Some physicians were reluctant to prescribe naloxone to patients who were 
dependent on opioids because they believed that their peers or their patients might 
perceive the action as encouraging or enabling opioid misuse behaviors (Gatewood, Van 
Wert, Andrada, & Surkan, 2016). Other physicians had misgivings that access to 
naloxone by laypersons would preclude seeking proper treatment after an overdose 
resuscitation (Gatewood et al., 2016). The physicians felt that underlying problems might 
not be identified or addressed if patients believed they could treat themselves with 
naloxone (Gatewood et al., 2016). Such perceptions and beliefs regarding the expanded 
access to naloxone may not be the norm among the medical community. The provision of 
training that highlights prescribing and using naloxone may help to alleviate the concerns 
that some health care professionals have regarding laypersons’ access to and 
administration of naloxone (Gatewood et al., 2016). 
Whether or not the expansion of naloxone access increases reckless behavior or 
discourages the cessation of opioid misuse remains a point of contention (Heavey, Chang, 
et al., 2018). Several studies indicated that expanded access to naloxone was not 
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associated with opioid misuse behaviors. For example, Marco et al. (2018) conducted a 
study of patients who presented to the emergency department with opioid overdose. The 
intent of the study was to understand the patients’ experiences involving the use of 
naloxone. Marco et al. found that the patients who had access to naloxone did not alter 
their opioid dose or frequency of opioid use as a result of the access. Among those 
patients who had possessed naloxone, 33% of them indicated they used opioids less often 
(Marco et al., 2018). 
Another example is a study conducted by J. D. Jones, Campbell, Metz, and Comer 
(2017) who observed current and former heroin users who were in and out of substance 
use treatment. J. D. Jones et al. sought to determine whether the provision of naloxone 
and opioid overdose training changed the participants’ drug use behaviors. J. D. Jones et 
al. used repeated-measures analysis of variance and found that heroin use decreased 
among the active users at the conclusion of the first and third months after the training 
and the provision of naloxone. J. D. Jones et al. concluded that access to naloxone did not 
increase opioid misuse behavior. 
The studies conducted by Marco et al. (2018) and J. D. Jones et al. (2017) were 
subject to several limitations. Marco et al. used a qualitative design and relied on self-
report data from patients of a single emergency department. The study lacked 
generalizability, and the results were based on the accuracy of the information provided 
by the patients, which might have biased the results. J. D. Jones et al. relied on self-report 
data and used a correlational design study, which precluded a causal inference 
determination. Despite these limitations, these studies provided evidence that supported 
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the expansion of public access to naloxone and refuted the claims that expanded access to 
naloxone promoted risky opioid use behavior. 
Gap in the Literature 
A search of the literature for studies that addressed how access to naloxone 
affected opioid use behavior regarding repeat overdose yielded only one study, which 
was conducted by Heavey, Chang, et al. (2018). To understand opioid use behaviors 
among patients enrolled in opioid use treatment, Heavey, Chang, et al. conducted in-
depth interviews with 20 inpatients to explore the patients’ perceptions regarding access 
to naloxone and the patients’ behavior, awareness, and attitude regarding the medication. 
Heavey, Chang, et al. found that all the patients except one were aware of naloxone and 
its purpose and that less than one half of the patients knew how to obtain naloxone or had 
ever possessed or administered the medication. Some of the patients, despite their 
knowledge about the life-saving ability of naloxone, prioritized maintaining the euphoric 
feeling from the opioid above that of reviving someone—or being revived—from a 
potential overdose (Heavey, Chang, et al., 2018). The accessibility to naloxone was a 
factor in several of the participants’ opioid use behavior in that the individuals reported 
increasing their usual dose of heroin when naloxone was present (Heavey, Chang, et al., 
2018). 
The study by Heavey, Chang, et al. (2018) was qualitative in nature and limited to 
a small sample of people who were undergoing opioid use treatment. Although repeat 
opioid overdose was not the outcome variable of interest in the study, the results provided 
insight that naloxone might be perceived as a safety net for those individuals who choose 
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to misuse opioids. The paucity of research focused on the accessibility of naloxone and 
the medication’s impact on opioid use behavior represented a gap in the literature. This 
current study may help fill that gap through a quantitative analysis of the relationship 
between opioid overdose demographics, naloxone accessibility, and repeat opioid 
overdose. 
Summary 
Preventing opioid overdose-related mortalities is an ongoing public health effort. 
The use of naloxone, an opioid antagonist, is a common practice used in reversing the 
effect of an opioid overdose (Klebacher et al., 2017; Rowe et al., 2015; Wheeler et al., 
2015). The literature is rife with studies involving opioid overdose and naloxone. A surge 
in studies published on these topics occurred within the past decade, which likely 
stemmed from the opioid epidemic in the United States. There was not, however, an 
abundance of studies published in which the diffusion of innovations theory served as the 
basis for research on naloxone use and repeat opioid overdose. The four elements of the 
theory, along with parenthetical entries that show how they related to the current study, 
are as follows: the innovation (naloxone), a communication system (public health 
communications about the importance of naloxone), time (the acceptability and extent of 
naloxone use), and a social system (the interconnected individuals and organizations 
involved in combating the opioid overdose crisis). The diffusion of innovations theory 
was appropriate as a framework because it focuses on behavioral changes (i.e., repeat 
opioid overdose) among people over time. 
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Professional emergency first responders such as LEO and EMS personnel provide 
timely, prehospital treatment with naloxone to revive opioid overdose victims. These 
professionals are also well positioned to provide overdose victims with information about 
treatment options for substance misuse disorder. The rescue roles of these emergency 
first responders are beneficial in other ways as well. For example, the data collected by 
these professionals may be used to monitor overdose and repeat overdose trends in 
communities (Lasher, et al., 2019). Additionally, the data collected on the number of 
doses required to revive overdose victims may help local public health officials monitor 
the potency of ingested opioids (Lasher et al., 2019). 
Historically, naloxone was reserved for administration by those within the 
medical profession. The medication has since been made available for use by members of 
the public via venues such as emergency departments, pharmacies, and community-based 
programs. The role of pharmacies in improving naloxone access is evolving, consistent 
with the provisions addressed in the Comprehensive Addiction and Recovery Act (2016). 
Pharmacies are located throughout communities, which makes the venues beneficial in 
providing accessibility to naloxone, particularly to opioid users in rural and underserved 
areas (Bachyrycz et al., 2017). Emergency departments are uniquely oriented to educate 
opioid users at risk for overdose and to provide the opioid users with take-home naloxone 
(Gunn et al., 2018). Such a unique opportunity is often unexploited by emergency 
departments because the departments lack adequate staffing or because the staff members 
lack the time to attend the requisite naloxone training (Gunn et al., 2018). If emergency 
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departments can overcome these barriers, they can help reduce community overdoses and 
repeat overdoses involving opioids (Gunn et al., 2018). 
Community-based naloxone programs can be used to distribute naloxone to 
populations in need of the medication, provide training on recognizing and responding 
appropriately to an opioid overdose, and link patients to support and recovery programs. 
Community-based naloxone programs are effective in improving the knowledge and 
confidence of family members of individuals who use opioids (Bagley et al., 2015). Also, 
the programs help public health policy makers communicate opioid overdose prevention 
strategies to communities and social networks (Bagley et al., 2015). Family members, 
community-based naloxone programs, emergency departments, and pharmacies are 
examples of the components of the social system described by Rogers (2003) in the 
diffusion of innovations theory. 
Deaths associated with opioid overdose continue to rise, making the problem a 
high priority among health and public health policy makers. Expanding the access of 
naloxone to laypersons is one approach in addressing the opioid overdose problem. The 
approach has not been well received by some people, including some health care 
professionals. Despite the beliefs by some that misbehaviors are associated with the 
expanded access to naloxone, ready access to the medication is crucial because not all 
opioid overdoses stem from the use of illicit opioids (Rudski, 2016). 
Little is known about the impact of the expanded accessibility of naloxone on 
opioid use behavior, including repeat opioid overdose. There is a dearth of research 
literature addressing the topic. Understanding the epidemiology of repeat opioid overdose 
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is beneficial in understanding the depth of the current opioid epidemic. The intent of this 
current study was to extend the literature regarding what is known about the impact of 
naloxone on opioid use behavior. This study was conducted to determine the relationship 
between the demographics (gender, age, and race), naloxone accessibility, and repeat 
opioid overdose. Information regarding the collection and analysis of data on the 
variables in the study is presented in Chapter 3. The research design, rationale, and 
methodology used in conducting the study are presented in Chapter 3 as well. 
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Chapter 3: Research Method 
The purpose of this study was to determine whether relationships existed between 
demographics, naloxone accessibility, and repeat opioid overdose in a Tennessee county. 
The selection of the research design for this study and the methodology that was used to 
test the research questions and their associated hypotheses are discussed in this chapter. 
Discussions of the research population, sampling strategy and procedures, 
operationalization of each variable, and data analysis plan are included as part of the 
methodology. Additionally, threats to the validity of the study and the ethical procedures 
employed in the study are presented. The chapter concludes with a summary. 
Research Design and Rationale 
In this study, there were five independent variables (age, gender, race, naloxone 
doses administered by professional first responders, and distribution of naloxone rescue 
kits) and one dependent variable (repeat opioid overdose). The independent variables of 
age, gender, and race were covariates. The variables were components of the research 
questions, which were structured to support the study of the effect of naloxone on opioid 
use behavior from a social and health perspective. The focus of the study’s research 
questions was on the quantitative examination of the predictor variables (age, gender, 
race, the naloxone dose administered, and the distribution of naloxone rescue kits) and 
their relationship to the outcome variable (repeat opioid overdose). 
A study is guided by its research questions and hypotheses, which, together with 
the study’s purpose, dictate the appropriate choice of research design (Crawford, 
Burkholder, & Cox, 2016). The research design provides a detailed strategy that will be 
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used to answer the research questions (Crawford et al., 2016). Typically, the research 
design comprises an inquiry approach, a design specific to that approach, and a rationale 
for selecting the approach and design (Crawford et al., 2016). The research’s approach to 
inquiry can be quantitative, qualitative, or a combination of the two, which is known as 
mixed methods. 
The quantitative approach involves the use of large amounts of numerical data 
along with statistical analyses to objectively and systematically explain an observation 
(McCusker & Gunaydin, 2015; Queirós, Faria, & Almeida, 2017). The approach’s 
strengths include its ability to make statistical comparisons between samples and test 
hypotheses; weaknesses include its inability to focus on contextual details and the need 
for complex statistical analysis procedures (McCusker & Gunaydin, 2015). The 
qualitative approach, on the other hand, involves the use of words as the data. Such data 
are generated during researcher-participant dialogues conducted to understand the 
perceptions, attitudes, and experiences of study participants (McCusker & Gunaydin, 
2015). Although the approach allows for a deeper understanding of the topic of interest, it 
is susceptible to emotional and subjective biases associated with the active, intimate role 
of the researcher (McCusker & Gunaydin, 2015). The mixed-methods approach includes 
a combination of the quantitative and qualitative methods and is beneficial in answering 
research questions that tend to be complex (McCusker & Gunaydin, 2015). Combining 
the quantitative and qualitative attributes is a strength of the mixed-methods approach; 
however, doing so can be time-consuming and expensive (McCusker & Gunaydin, 2015). 
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Of the three approaches, the quantitative approach was the most appropriate 
choice for the current study because the data collected to answer the research questions 
were numerical and analyzed using statistical tests. Additionally, the use of de-identified, 
secondary data and the restricted access to interview patients who overdosed on opioids 
more than one time precluded the selection of a qualitative or mixed-methods approach. 
The next step after determining the approach is to choose a design consistent with the 
approach. Selecting the appropriate design for a quantitative study is crucial in answering 
research questions. Descriptive, experimental, and correlational are three commonly used 
quantitative designs. 
Consistent with its nomenclature, the descriptive design is used to describe 
observed occurrences (i.e., the variables). With the design, statistical data such as 
frequencies/counts, means, and standard deviations are collected on the variables and 
examined (Cook & Cook, 2016). Although the descriptive research design does not 
permit the determination of relational or causal inferences between the variables, it offers 
the benefit of providing reliable measures of phenomena, formulating theory, and serving 
as a basis for subsequent research using qualitative or other quantitative research designs, 
such as relational and experimental designs (Cook & Cook, 2016). 
Experimental designs are used to examine causal inference between the variables, 
specifically whether a change in the independent variable is responsible for a change in 
the dependent variable (Cook & Cook, 2016). The design includes use of experimental 
and control samples partitioned by the researcher, and the researcher systematically 
manipulates the independent variable and measures its effect on the dependent variable 
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(Cook & Cook, 2016; Queirós et al., 2017). Despite their use in determining causality, 
experimental designs can be expensive, difficult to replicate, and susceptible to ethical 
concerns (Cook & Cook, 2016; Queirós et al., 2017). Additionally, the small sample 
often employed in the design might not be representative of the population from which 
participants were selected (Queirós et al., 2017). 
Correlational research is the third quantitative design. Correlational research is 
exploratory in that it is used to determine whether relationships exist between variables 
(Queirós et al., 2017). The design does not involve the manipulation of variables or a 
determination of whether the independent variable causes a change in the dependent 
variable (Cook & Cook, 2016; Queirós et al., 2017). Instead, the design is used to 
examine whether and how the variables are related, whether the variables are responsible 
for differences observed among groups, and whether there is enough evidence to explore 
causality through experimental research (Cook & Cook, 2016). 
In light of the goal of the current study to examine the relationships between 
demographics, naloxone dose administrations, naloxone kit distributions, and repeat 
opioid overdose, the correlational research design was the appropriate quantitative 
design. The descriptive design was not appropriate because examining the relationship 
between variables is not part of its design feature. Because there was no manipulation of 
the variables or an intent to make a causal determination, the experimental design was 
inappropriate. An additional rationale that made the choice of the correlational design 
appropriate was the efficiency associated with the time and resources necessary to 
conduct the study. The design permitted the exploration of a large amount of data on 
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different variables in a short time frame, as the data on each variable were collected 
simultaneously and at one point in time. 
Methodology 
The research methodology includes the steps that will be followed to obtain 
answers to the research questions (Crawford et al., 2016). Typically, the methodology 
addresses the study participants, sampling strategy, data instrumentation, and data 
collection procedures (Crawford et al., 2016). Such procedures should include how the 
data will be obtained, structured, cleaned, and analyzed (Crawford et al., 2016). 
Population 
The setting of this study was a county in Tennessee. The population of interest 
was the county’s approximately 80,000 residents (U.S. Department of Commerce [DOC], 
U.S. Census Bureau [USCB], n.d.). Racially, the population was 91.7% White, 4.0% 
Black, 3.1% Hispanic, 1.5% Asian, 0.5% American Indian/Alaska Native, and 0.1% 
Native Hawaiian/Pacific Islander (DOC, USCB, n.d.). There were slightly more females 
than males in the population, with ratios of 51.3% and 48.7%, respectively (DOC, USCB, 
n.d.). The median age was 43.3 years, with 21% of the population under 18 years of age, 
58.9% between 18 and 64 years of age, and 20.1% 65 years of age and older (DOC, 
USCB, n.d.). 
Sampling and Sampling Procedures 
A sampling strategy that is well planned and carefully executed is necessary to 
ensure that the results of the study are not biased by the participant selection process 
(Martínez-Mesa, González-Chica, Duquia, Bonamigo, & Bastos, 2016). The strategy 
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includes establishing the sampling unit, target population, sampling frame, and sample. 
Understanding the sampling strategy helps contextualize the sample’s representativeness 
of the population from which it was selected (Lohr, 2010). The sampling unit is the 
element under observation (i.e., an individual, household, or community) that has the 
potential to be included in the sample (Lohr, 2010). The collection of the sampling units 
constitutes the target population, which is used to make inferences (Lohr, 2010). The 
sampling frame is a listing of the sampling units in the study population (Lohr, 2010). 
Finally, the sample is a subset of the sampling units selected from the target population 
(Martínez-Mesa et al., 2016). Results from the sample are used to make inferences to the 
target population with a degree of accuracy (Lohr, 2010). 
Secondary data were used in this study. The data were obtained from two sources: 
the county’s EMS and a community-based naloxone program. Data use agreements, 
which described the criteria necessary for the sample, were used to obtain the data sets. 
The data sets were de-identified before they were provided for use in the study. 
The individual was the sampling unit in this study. The sampling frame was a 
listing of the individuals to whom the EMS professionals responded based on 911 calls 
that involved suspected opioid overdose during a specified time frame. The individuals 
who did not require the administration of naloxone were excluded from the sampling 
frame. The remaining individuals represented the sample. 
 Erdfelder, Faul, and Buchner’s (1996) power analysis program G*Power was 
used to calculate the size of the two samples that were used in the current study. In 
calculating the first sample, binary logistic regression was used as the statistical test to 
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examine the relationships between the independent variables (age, gender, race, and the 
naloxone dose administered) and the dependent variable (repeat opioid overdose). 
Choosing the two-tailed z-tests option in G*Power allowed the selection of logistic 
regression for the statistical test. The effect size was specified to be measured as an odds 
ratio. The two-tailed test was selected because there was no presumption about the 
direction of an observed difference regarding the independent and dependent variables 
(Parab & Bhalerao, 2010). 
Assumptions were made regarding the logistic regression power analysis 
calculation of the first of two samples used in the study. The assumed event rates under 
the null and alternative hypotheses were .5 and .6, respectively, which corresponded to an 
odds ratio of 1.5. Because there were multiple independent variables in the study, the 
squared multiple correlation value was assumed to be 0.1. Additionally, a normal 
distribution of the independent variables was assumed. The probability of error (or alpha) 
of .05 and the statistical power of .80, a value recommended by Cohen (1992) when 
rationales for other power values are unavailable, were selected. Statistical power, which 
refers to the probability of rejecting the null hypothesis when it is false, is a function of 
the alpha level of significance, the sample size, and the size of the effect (Cohen, 1992). 
Using .80 for the power is commonly accepted as the value necessary to select an 
adequate sample size that will detect a statistically significant effect size with confidence 
(Undersander, Kettler, & Stains, 2017). Anything lower than .80 will likely diminish the 
level of confidence that the study results are truly reflective of the sample (Undersander 
et al., 2017). Based on the input parameters, the minimum sample size necessary to detect 
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a statistically significant relationship between the independent variables and the 
dependent variable was determined to be 231. 
In calculating the second sample with G*Power, Poisson regression was used as 
the statistical test to examine the relationship between the independent variable 
(distribution of naloxone rescue kits) and the dependent variable (repeat opioid 
overdose). Other selections included the z-test, which allowed the selection of the Poisson 
regression test; 80% for the power; and .05 for the probability of error. Assumptions 
made in selecting the parameters were that the distribution of the independent variables 
was normal, the event base rate was equal to 1, the change in the dependent variable with 
each unit increase of the independent variable was 10%, and the independent and 
dependent variables was examined in 7-day increments (i.e., the mean exposure). With 
the input parameters, a minimum sample size necessary to detect a statistically significant 
relationship between the independent and the dependent variables was determined to be 
123. 
Operationalization 
Naloxone access was operationalized as two variables: the naloxone dose 
administered by professional first responders and the distribution of naloxone rescue kits 
through a community-based program. Although there were other means by which 
individuals could access naloxone (i.e., pharmacies, emergency departments, and local 
health departments), the venues represented by the two variables were chosen because 
they were included in the literature along with results that were used as comparisons to 
the findings of the current study. The demographics of interest in this study were the age, 
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gender, and race of individuals who received naloxone because of an opioid overdose. 
Age, gender, race, the naloxone dose administered by professional first responders, and 
the distribution of naloxone rescue kits were the independent variables in the current 
study; repeat opioid overdose was the sole dependent variable. Age can be a continuous 
or categorical variable, depending on how the data are collected and coded. Nominal 
variables, which can have two or more categories in no particular order; dichotomous 
variables, which have two mutually exclusive categories; and ordinal variables, which 
have two or more ranked levels, are the types of categorical variables. 
So that the variable of age could be compared with results in the literature, age 
was analyzed as a categorical, ordinal variable with eight levels in the current study. The 
levels of the variable, which were age groups in years, were coded as 1 = less than 15, 2 
= 15–24, 3 = 25–34, 4 = 35–44, 5 = 45–54, 6 = 55–64, 7 = 65–74, and 8 = 75 or older. 
Gender was a categorical, dichotomous variable that was coded as 1 = male and 2 = 
female. Race was a categorical, nominal variable with three categories coded as 1 = 
White, 2 = Black, and 3 = Other. The variable that represented the naloxone dose 
administered by professional first responders was analyzed as a continuous variable. The 
unit of measure of the administered dose was in milligrams (mg). The distribution of 
naloxone rescue kits was also analyzed as a continuous, interval variable because it was a 
measure of the number of kits distributed through the community naloxone program. The 
dependent variable, which was repeat opioid overdose, represented the number of 
nonfatal or fatal opioid overdoses that occurred more than one day after the first overdose 
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in which naloxone was administered (Olfson et al., 2018). Repeat opioid overdose was 
analyzed as a categorical, dichotomous variable that was coded as 1 = no and 2 = yes. 
Data Analysis Plan 
The descriptive and inferential statistical analyses in this study were performed 
using IBM SPSS Statistics (Version 25). The software was used also to screen and clean 
the data sets. The screening and cleaning processes included a visual examination of the 
data sets to determine whether there were outliers among the data or whether any of the 
data were missing or seemed abnormal. Missing data can reduce the size of the study’s 
sample and affect the reliability of the study if the results were biased by the missing 
information (Kwak & Kim, 2017). Outliers can also introduce bias in a study’s results, 
especially results derived from standard deviation and mean calculations (Kwak & Kim, 
2017). The mean and standard deviation are sensitive to outliers in that the outliers can 
cause the statistics to be overestimated or underestimated (Kwak & Kim, 2017). 
Determining the relationship between demographics, naloxone accessibility, and 
repeat opioid overdose in a Tennessee county was the purpose of this study. The research 
questions and the hypotheses that guided the examination of the relationships are as 
follows: 
Research Question 1: What is the association between age and repeat opioid 
overdose? 




Ha1: There is a statistically significant association between age and repeat opioid 
overdose. 
Research Question 2: What is the association between gender and repeat opioid 
overdose? 
H02: There is no statistically significant association between gender and repeat 
opioid overdose. 
Ha2: There is a statistically significant association between gender and repeat 
opioid overdose. 
Research Question 3: What is the association between race and repeat opioid 
overdose? 
H03: There is no statistically significant association between race and repeat 
opioid overdose. 
Ha3: There is a statistically significant association between race and repeat opioid 
overdose. 
Research Question 4: What is the association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose? 
H04: There is no statistically significant association between the naloxone dose 




Ha4: There is a statistically significant association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose. 
Research Question 5: What is the association between the distribution of naloxone 
rescue kits and repeat opioid overdose? 
H05: There is no statistically significant association between the distribution of 
naloxone rescue kits and repeat opioid overdose. 
Ha5: There is a statistically significant association between the distribution of 
naloxone rescue kits and repeat opioid overdose. 
Descriptive analysis. Descriptive statistics are useful in summarizing 
observations so that the information can be conveyed in a manner that is easy to 
understand (Mishra et al., 2019). The three types of descriptive statistics are measures of 
frequency (i.e., frequencies and percentages), measures of central tendency (i.e., mean, 
median, or mode), and measures of variability (i.e., variance, standard deviation, standard 
error, range, interquartile range, and percentile; Mishra et al., 2019). The measures of 
frequency were used to summarize the characteristics of age, gender, race, and repeat 
opioid overdose because the variables were categorical. The variables that represented the 
distribution of naloxone rescue kits and the naloxone dose administered by professional 
first responders were continuous variables, so their characteristics were described using 
the measures of central tendency or the measures of variability. 
Inferential analysis. Inferential statistics help researchers draw conclusions from 
data used in the study. The intent of such statistics is to make inferences—or 
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generalizations—about a larger population based on the statistical analyses conducted on 
a sample selected from the population (Mishra et al., 2019). Researchers rely on 
statistical tests to help make the inferences. The level of measurement of a study’s 
variables is important in determining which statistical test is best to analyze the 
quantitative data (Parab & Bhalerao, 2010). Multiple logistic regression can be used to 
analyze the relationship between a dichotomous dependent variable and several 
independent variables that are categorical, continuous, or a combination of the two 
(Daniel & Cross, 2013; Warner, 2013). The dependent variable (repeat opioid overdose) 
in the first four research questions was categorical and dichotomous; the independent 
variables of age, gender, and race in Research Questions 1, 2 and 3, respectively, were 
categorical; and the independent variable (the naloxone dose administered by 
professional first responders) in Research Question 4 was continuous. The use of multiple 
logistic regression to analyze the data and to answer Research Questions 1 through 4 was 
appropriate. 
Predicting the odds of the dependent variable on the measures of the independent 
variable is the goal of using multiple logistic regression as an analysis test (Warner, 
2013). Multiple logistics regression yields an odds ratio, which is a measure used to 
determine the strength of an association between the independent and dependent 
variables. In the current study, the odds ratios were interpreted as how much greater or 
lesser the odds were that the sample characterized by the independent variable would 
experience the dependent variable (see Daniel & Cross, 2013). 
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Multiple logistic regression requires adherence to the assumptions that (a) the 
dependent variable be dichotomous; (b) the categories on the dependent variable be 
statistically independent of each other, exhaustive, and mutually exclusive; and (c) one or 
more independent variables be categorical or continuous (Warner, 2013). The dependent 
variable (repeat opioid overdose) was dichotomous in that the variable had two categories 
(yes and no), which were independent of each other, exhaustive, and mutually exclusive. 
The first two assumptions were satisfied. The four independent variables were categorical 
or continuous, which fulfilled the requirement of the third assumption. 
Another assumption of multiple logistic regression requires that the model 
predicted by SPSS be consistent with the outcome data, a verification process known as 
the goodness of fit test (Warner, 2013). In the current study, this assumption was tested 
using the Hosmer-Lemeshow goodness of fit (H-L) test in SPSS. The observed and the 
expected frequencies predicted by the logistic regression were compared using a chi-
square test, which helped assess the level of deviation between the two sets of 
frequencies (see Warner, 2013). A large H-L chi-square value and a test statistic (i.e., p 
value) that is less than .05 mean that the model’s expected frequencies deviate 
significantly from the observed frequencies, which indicates a poor model fit (Warner, 
2013). A good-fitting model has a small H-L chi-square value and a p value greater than 
.05, which is interpreted to mean the model’s expected frequencies fit the observed 
frequencies at an acceptable level (Warner, 2013). 
The Poisson regression analytical test, which is useful in determining whether an 
independent variable influences the rate of events (i.e., the dependent variable) over a 
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period of time, was used to answer Research Question 5. Poisson regression is also useful 
when the dependent variable is represented as frequency or count data. In Poisson 
regression, the independent variable can be categorical or continuous and is used to 
predict the dependent variable measure, which is expected to vary as a log-linear function 
of the independent variable (Chakraborty, Maiti, & Strecher, 2018). Because the 
independent variable (distribution of naloxone rescue kits) in Research Question 5 was 
continuous and the dependent variable (repeat opioid overdose) was measured as count 
data, the use of Poisson regression was appropriate to answer the research question. 
The measure of effect size in Poisson regression analysis is the rate ratio. In 
SPSS, the effect size is reported as the exponentiated value of the regression coefficient 
(i.e., ExpB), which represents the change in the expected dependent variable when the 
independent variable increases by one unit (Chakraborty et al., 2018). In the current 
study, the rate ratio value was interpreted as the change in repeat opioid overdose events 
for each extra naloxone rescue kit that was distributed. 
Poisson regression requires adherence to the assumptions that (a) the dependent 
variable is composed of count data, (b) the observations on the dependent variable are 
independent of each other, (c) the counts demonstrate a Poisson distribution, and (d) the 
mean and variance distributions are equivalent (Huang & Cornell, 2012). The dependent 
variable (repeat opioid overdose) in Research Question 5 was measured as count data, 
which satisfied the first assumption. An individual can have multiple repeat opioid 
overdoses as long as the events are treated as independent observations. The definition of 
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repeat opioid overdose used in the current study, ensured the independence of 
observation assumption was met. The last two assumptions were tested using SPSS. 
A p value of .05 was used as the level of statistical significance during the 
hypothesis testing in this study. The p value, also known as the alpha level, represents the 
probability of observing the results if the null hypothesis were true (du Prel, Hommel, 
Roehrig, & Blettner, 2009). Confidence intervals, which provide a range of the accuracy 
of the estimate that is likely to contain the true value of the population parameter of 
interest (Frankfort-Nachmias & Leon-Guerrero, 2015), were used in reporting the odds 
ratios and rate ratios in the study. The 95% confidence interval is frequently used in 
research, and it was used in this present study. The measured effects were statically 
significant at the .05 alpha level if the value of 1 (which means no discernible difference) 
was not contained within the confidence interval. 
Threats to Validity 
The quality of a quantitative study depends on its validity, i.e., the ability to depict 
the real meaning of the phenomenon that is under observation (Babbie, 2017). The 
traditional components of validity are internal validity and external validity. Other 
components include construct validity and statistical conclusion validity. The components 
of validity characterize the representativeness of the sample, the attributes of the 
population from which sample was obtained, the data collection and analysis, and the 
study methods in such a way that allows inferences to be drawn from the results of the 
study (Stewart & Hitchcock, 2016). Conditions referred to as threats to validity can 
interfere with the outcome of the study. Threats to validity minimize the internal, 
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external, construct, and statistical conclusion validities of a study (Holgado-Tello, 
Chacon-Moscoso, Sanduvete-Chaves, & Perez-Gil, 2016). 
Internal Validity Threats 
Internal validity refers the extent to which the independent variable made a 
significant difference in the dependent variable (Campbell, 1957). Seven types of 
extraneous variables can impact the internal validity of a study: (a) selection, which is the 
potential bias associated with how the participants are selected; (b) history, which refers 
to the specific events experienced by the participants; (c) maturation, which refers to the 
biological changes that occur among the participants; (d) regression, which is the 
statistical regression of measures on the participants toward the mean value; (e) testing or 
measuring outcomes associated with the participants; (f) instrument decay, which 
involves changes in an instrument that affect the instrument’s ability to measure 
accurately; and (g) mortality, which is the differential loss of participants from the study 
(Campbell, 1957; Flannelly, Flannelly, & Jankowski, 2018). Controlling the extraneous 
variables is crucial in achieving a high degree of internal validity, meaning any measured 
changes in the dependent variable were most likely influenced by the independent 
variable (Flannelly et al., 2018). 
Selection can threaten a study’s internal validity. Choosing study participants 
through randomization procedures can minimize the threat. Because the sample in the 
current study included all of the individuals who met the selection criteria, selection had 
no impact on the internal validity. Three variables (i.e., age, gender, and race) associated 
with the participants in the current study could have been confounders and could have 
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influenced the dependent variable. In a systematic literature review and meta-analysis, 
Brady, Giglio, Keyes, DiMaggio, and Li (2017) found that being White, male, and among 
the 35–44 age group were statistically significant risk factors of nonfatal and fatal 
prescription opioid overdose. To minimize the potential threat to the internal validity of 
the current study, the variables of age, race, and gender were included as independent 
variables and were examined during the statistical analyses. Doing so minimized 
confounding as a selection threat to this study’s internal validity. 
As discussed by Campbell (1957), the threat of history refers to specific events or 
stimuli that occur during the study’s observation period and are experienced by the 
participants such that the events or stimuli influence the results of the study. In the 
strictest sense of the term, the threat of history was not applicable in the current study 
because anonymous data were collected only once on the participants and only at a single 
point in time. Because Research Question 5 focused on the distribution of naloxone 
rescue kits and repeat opioid overdose observed over time, history might have been a 
threat to the internal validity. For example, unmeasured environmental confounders such 
as the variations in opioid prescriptions written by physicians, the availability of opioid 
misuse treatment facilities, and the illicit opioid market trends could have influenced the 
outcome measure (see McClellan et al., 2018; and Wagner et al., 2016). Because 
anonymous data were collected only once on the participants and only at a single point in 
time, the threats associated with maturation and mortality were not applicable in the 
current study. Also, there were no threats related to testing, regression, or instrument 
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decay in this study because no tests or examinations were administered to obtain 
biological or psychological information about the participants. 
External Validity Threats 
The extent to which the study’s results can be applied to other populations or 
settings is known as external validity (Campbell, 1957). The credibility of research relies 
on its external validity, meaning that the study results, with a high level of confidence, 
can be extrapolated to other populations, places, and times (Pound & Ritskes-Hoitinga, 
2018). Selection can affect external validity through interaction with the sample units 
(i.e., the study participants). For example, the study results may be different if another 
group of participants is used (Campbell, 1957; Stewart & Hitchcock, 2016). The 
interaction effects of selection reduce the representativeness of the sample and, thereby, 
the generalizability of the results to the target population if there are effects in the 
environment that can influence the outcome (Campbell, 1957). 
Because all eligible overdose events were included in the sample of the current 
study, a sampling selection procedure was unnecessary. The external validity associated 
with representativeness, therefore, was not compromised. On the other hand, the results 
of this study may not be generalizable to other populations or environments. Target 
populations in which individuals overdose on opioids may have demographic 
compositions that are different from those in the current study. Additionally, other target 
populations may have more or less access to opioids (i.e., via physician prescriptions or 
illegal drug markets), naloxone (i.e., via community-based programs or pharmacies that 
dispense naloxone under standing orders), or substance use treatment facilities, all of 
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which are factors that may influence the rates of opioid overdose and repeat overdose. To 
address the potential validity threat associated with generalizability to other populations 
or settings, a strategy suggested by Stewart and Hitchcock (2016) was employed in the 
current study. The strategy included conducting a thorough literature review for studies 
related to the variables in the current study and comparing the findings from those studies 
with the findings of the current study (see Stewart & Hitchcock, 2016). 
Construct Validity Threats 
Construct validity is the extent to which the conclusions of a research study truly 
reflect the construct that was operationalized, meaning that the construct (or idea) was 
translated into something real or tangible (Trochim & Donnelly, 2008). Failure to analyze 
and to develop the construct of interest adequately can threaten construct validity 
(Holgado-Tello et al., 2016). The threat of construct validity in the current study was 
mitigated by the use of a clear definition of the dependent variable (repeat opioid 
overdose) that was based on the literature. Additionally, naloxone access was defined 
based on prior research, and the phenomenon was operationalized as two independent 
variables that were measurable and analyzable. 
Statistical Conclusion Validity Threats 
Statistical conclusion validity refers to the extent to which a statistical inference 
can be made about the measured relationship between the dependent and independent 
variables (Cor, 2016). Statistical conclusion validity focuses on whether the observed 
relationship between the predictor and outcome variables was attributed to a true effect or 
to chance (Cor, 2016). Threats to statistical conclusion validity can result in type I and 
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type II errors, which can result in inaccurate inferences from the data (Creswell, 2014). A 
type I error, also known as the alpha risk, occurs when the null hypothesis—a 
determination of no statistically significant difference—is rejected although it is true 
(Daniel & Cross, 2013). Such an error means that what was detected was due solely to 
chance and that the researcher incorrectly interpreted the data to mean there was a 
difference when there was not a difference. A type II error, known as the beta risk, occurs 
when the null hypothesis is not rejected when it is false (Daniel & Cross, 2013). A type II 
error means that the observed difference was not due solely to chance and that the 
researcher incorrectly interpreted the data to mean there was no difference when there 
was a difference. 
Statistical conclusion validity threats are caused by choosing a statistical power 
that is inadequate, selecting an incorrect statistical technique based on the characteristics 
of the data (i.e., parametric versus nonparametric tests), or failing to ensure that statistical 
assumptions are not violated (Cor, 2016; Creswell, 2014). In conducting the statistical 
power analysis to determine the sample size for this current study, .80 was used for 
power. According to Dorey (2011), the power of .80 is sufficient to use in correlational 
studies of a retrospective nature. Because the sample used in this current study comprised 
at least the number of participants calculated in the G*Power analysis, the statistical 
conclusion validity was not threatened by an inadequate statistical power. The threat of 
inappropriate use of statistical techniques was not a concern in this study. The dependent 
variable in Research Questions 1 through 4 was categorical and was analyzed using 
logistic regression. The dependent variable in Research Question 5 was a measure of 
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count data and was analyzed using Poisson regression. The assumptions associated with 
multiple logistic regression and Poisson regression used in the current study were 
identified. Measures were implemented to ensure the assumptions were not violated, 
which reduced the threat to the statistical conclusion validity in this study. 
Ethical Procedures 
Research should always be conducted ethically, ensuring the protection of study 
participants and the organizations associated with the research. Obtaining informed 
consent and making certain that the participants are not physically or mentally harmed 
are crucial aspects associated with the use of participants in research (Rudestam & 
Newton, 2015). The prevention of harm subsumes the assurance that the participants’ 
anonymity and their confidentiality will be maintained. The integrity, reputation, and 
copyright interests of the organizations involved with the research must be protected as 
well (George, 2016). 
Secondary data were used in this quantitative study. The data were de-identified, 
and there were no interactions with the subjects of the study, which assured anonymity of 
the participants. Data were collected from a county’s EMS and from a community-based 
naloxone program. I had no affiliation with the organizations. There were no conflicts of 
interest regarding power differentials or conducting research in my work environment. 
Because there were no interactions with the study participants, the use of incentives was 
not applicable. 
Data from the EMS and the community-based naloxone program were collected 
through the use of data use agreements. The data use agreements indicated that only a 
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limited data set of the variables in the study was needed and that the data set must contain 
only de-identified data (i.e., no names or any other direct identifiers to the individuals). 
The results of this study will be shared with the organizations. Because there were no 
interactions with the subjects of this study and because there was no collection of primary 
data, obtaining confidentiality disclosures and written informed consents was not 
applicable to the study. 
The data use agreements specified that the data sets would be safeguarded to 
prevent disclosure. The data sets were stored and accessed only by me on my personal 
computer. Encryption software was installed on my computer and was used to encrypt the 
data sets. Analyses of the data sets were performed using SPSS software on my 
computer. No software that was linked directly to the internet was used to analyze the 
data sets. The data will be retained for 5 years and then will be deleted permanently from 
my computer. 
The reporting aspect of research, which is often overlooked, can jeopardize the 
anonymity of study participants (Babbie, 2017). For example, responses provided by 
members of a small community might be recognizable by others in the community even 
if the data were de-identified (Babbie, 2017). There were no responses or personal 
information collected on the participants in this study, and the results were discussed as 
an aggregate (i.e., an age group) rather than at the level of the individual, a precaution 
that represented another mechanism of ensuring the anonymity of the participants. 
Conducting research ethically also means that researchers are responsible for 
being objective in their reporting, meaning they should report undesirable results as well 
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as the desirable results (Babbie, 2017). The undesirable (or negative) findings may 
benefit future research by indicating, for example, that there may not be a relationship 
between certain variables (Babbie, 2017). Positive and negative findings were included 
and discussed in this current study. 
Approval from the institutional review board (IRB) was a prerequisite to the 
collection of any data in this study despite that secondary, de-identified data were used 
and despite that no participants were recruited for the study. After approval from the IRB, 
the secondary data were collected and analyzed. Adherence to the ethical considerations 
ensured that this study was conducted ethically. 
Summary 
To determine whether relationships existed between opioid overdose 
demographics, naloxone accessibility, and repeat opioid overdose in a Tennessee county, 
a quantitative, correlational study with a cross-sectional design was conducted. Five 
research questions and their associated hypotheses guided the examination of the 
relationships. In the study, there were five independent variables (age, gender, race, the 
naloxone dose administered by professional first responders, and distribution of naloxone 
rescue kits) and one dependent variable (repeat opioid overdose). The variables were 
analyzed using descriptive and inferential statistics. The nature of the variables warranted 
the use of multiple logistic regression and Poisson regression in the inferential analyses. 
Validity threats can jeopardize the quality of a quantitative study. Internal, 
external, construct, and statistical conclusion are types of validity threats that should be 
recognized and managed before and during a study. Adherence to ethical procedures is 
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critical when planning and conducting a study as well as when reporting the results of a 
study. In Chapter 4, the data collected for this current study and the results of the 
statistical analyses are discussed. 
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Chapter 4: Results  
Naloxone is a life-saving pharmaceutical that is widely known to be effective in 
reversing an opioid overdose. However, what is not widely known, nor has been fully 
explored, is whether the medication precipitates opioid abuse (i.e., repeat overdose 
behavior). The purpose of this quantitative, correlational study was to examine the 
relationship between demographics, naloxone accessibility, and repeat opioid overdose in 
a Tennessee county. The research questions and their associated null and alternative 
hypotheses were as follows: 
Research Question 1: What is the association between age and repeat opioid 
overdose? 
H01: There is no statistically significant association between age and repeat opioid 
overdose. 
Ha1: There is a statistically significant association between age and repeat opioid 
overdose. 
Research Question 2: What is the association between gender and repeat opioid 
overdose? 
H02: There is no statistically significant association between gender and repeat 
opioid overdose. 
Ha2: There is a statistically significant association between gender and repeat 
opioid overdose. 




H03: There is no statistically significant association between race and repeat 
opioid overdose. 
Ha3: There is a statistically significant association between race and repeat opioid 
overdose. 
Research Question 4: What is the association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose? 
H04: There is no statistically significant association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose. 
Ha4: There is a statistically significant association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose. 
Research Question 5: What is the association between the distribution of naloxone 
rescue kits and repeat opioid overdose? 
H05: There is no statistically significant association between the distribution of 
naloxone rescue kits and repeat opioid overdose. 
Ha5: There is a statistically significant association between the distribution of 
naloxone rescue kits and repeat opioid overdose. 
This chapter includes the process employed in collecting and analyzing the data 
used in this study and the results of the statistical analyses. Information about the data 
source and the sample related to the target population is presented first. Next, the 
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descriptive statistics of the sample and the findings of the statistical analyses are 
discussed. The chapter concludes with a summary and segue to Chapter 5. 
Data Collection 
After approval from the Walden University IRB (#02-21-20-0670103), data were 
requested and received from a Tennessee county’s EMS and a community-based 
naloxone program. The community-based program data set consisted of the number of 
naloxone kits distributed and the dates of the distributions, which ranged from November 
2017 to December 2019. In total, there were 791 naloxone kits distributed on 40 days 
during the time frame. Each kit contained two 4-mg doses of naloxone. The EMS data set 
consisted of a database printout of 971 de-identified records of dispatches associated with 
overdoses from July 2016 to December 2019. 
Data Screening and Cleaning 
An examination of the data received from the community-based naloxone 
program in an Excel spreadsheet indicated seven duplicate line items. The duplicate 
entries were removed. There were 674 naloxone kits (representing 5,392 mg of naloxone) 
distributed during the time frame. The initial distribution of the naloxone kits via the 
program began on November 28, 2017. Figure 3 displays the monthly distribution of the 




Figure 3. Naloxone kits distributed by month (November 2017 to December 2019). 
The EMS data set was transferred to a Microsoft Excel spreadsheet and examined 
for missing information regarding the study variables. In two of the recorded overdose 
events, the dose of naloxone administered was recorded in units other than milligrams, so 
the records were removed from the data set. The gender was not listed on two recorded 
overdose events, so the two entries were removed as well. There were no other 
discrepancies or missing data identified in the EMS data set. The remaining 967 recorded 
overdose events represented the sampling frame. The characteristics of the sampling 





Characteristics of Sampling Frame 
Characteristics Overdose dispatches (N = 967) 
Gender, no. (%)  
 Male  483 (49.9) 
 Female  484 (50.1) 
Age (in years)   
 Mean  40.4 
 Median  38.0 
 Range  1–99 
Race, no. (%)  
 White  920 (95.1) 
 Black  28 (2.9) 
 Other  19 (2.0) 
Repeat overdose, no. (%)  
 0 repeat overdoses  884 (91.4) 
 1 repeat overdose  63 (6.5) 
 2 repeat overdoses  16 (1.7) 
 3 repeat overdoses  3 (.3) 
 4 repeat overdoses  1 (.1) 
Naloxone administered, no. (%)  
 Yes  386 (39.9) 
 No  581 (60.1) 
Naloxone dose, mg  
 Mean ± SD  1.80 ± .98 
 Median  2.0 
 Range  0.5–8.0 
Note. No. = number; mg = milligram; SD = standard deviation. 
 
Figure 4 depicts the opioid overdose events recorded by month by the county 
EMS from July 2016 through December 2019. Figure 5 displays the repeat opioid 




Figure 4. Opioid overdose events by month (July 2016 to December 2019). 
 




An examination of Figure 4 indicated that more than 10 opioid overdose events 
occurred each month, and more than 20 events occurred in over 80% (n = 34) of the 
months. The annual means of the opioid overdose events in 2016 (based on 6 months), 
2017, 2018, and 2019 were 26.8, 24.8, 22.3, and 20.1, respectively, which indicated that 
the opioid overdose events decreased compared to the prior year. Contrastingly, Figure 5 
shows a consistent increase in the repeat opioid overdose events through 2018, followed 
by a decrease in 2019. The average number of repeat events in 2016, 2017, 2018, and 
2019 were 1, 2.3, 2.5, and 1.7, respectively. The peak number of repeat opioid overdose 
events in a single month during the observation period was five, which was in December 
2017. 
Data Manipulation 
Microsoft Excel was used to create and code dummy variables for the 
independent categorical variables of gender and race and for the dependent variable, 
repeat overdose. The spreadsheet was also used to transform the independent continuous 
variable of age into a categorical, ordinal variable with eight levels. No data manipulation 
was necessary for the independent continuous variable, which was the naloxone dose 
administered by professional first responders during opioid overdose events. The Excel 
spreadsheet data were imported into SPSS, which was used to select and analyze only the 
cases (i.e., overdose events) in which naloxone was administered. The 386 selected cases 
represented the study sample and were used in conducting a multiple logistic regression 
analysis to answer Research Questions 1 through 4. 
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Two samples were used in the current study. The first sample was derived from 
the recorded overdose dispatches that were included in the EMS data set. To answer 
Research Question 5, it was necessary to create a new data set (i.e., the second sample) 
using the EMS data set and the community-based naloxone program data set. The date 
variable was the key variable in both data sets that permitted the linking procedure. Each 
record included the date (i.e., the end date of each week) associated with the distribution 
of naloxone kits and the number of repeat overdoses from January 2017 to December 
2019. The new data set had 156 records, which represented the 156 weeks of the study’s 
time frame. Because the sampling unit was the week, the size of the second sample was 
156. 
Univariate Analysis 
A univariate analysis was conducted using SPSS to determine whether to include 
the covariates (i.e., the independent variables of gender, age, race, and the naloxone dose 
administered by professional first responders) in the multiple logistic regression model. 
The results of each independent variable analysis are listed in Table 2. Gender was the 






Independent Variables in the Univariate Analysis 
Factors Exp(B) p value (Wald test) 
Gender (male-female comparison)  .35   .01  
Age (compared to 15–24) 
 25–34  .88   .84  
 35–44 1.13   .85  
 45–54  .72   .62  
 55–64  .42   .28  
 65–74  .96   .96  
 75 and over  .00 1.00  
Race (compared to White) 
 Black 1.90   .42  
 Other  .00 1.00  
Naloxone dose 1.17   .34  
 
Conducting univariate analyses helps determine which independent variables are 
best to use in predicting the dependent variables. Typically, the multiple logistic 
regression analysis is conducted using only the independent variables that are statistically 
significant in the univariate analyses. Although gender was the only statistically 
significant variable in the univariate analyses, all covariates were included in the multiple 
logistic regression analysis. 
Data Analysis Results 
Descriptive Statistics – Sample 1 
The descriptive statistics associated with the first sample are presented in Table 3. 
The sample consisted of more males (55.2%) than females (44.8%), the reverse of the 
county’s population in which there were more females (51.3%) than males (48.7%). 
Unlike the sampling frame, the sample comprised no individuals younger than 15 years 
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of age. The largest age category was the 25–34 (23.6%), followed by the 35–44 and 45–
54 categories, both of which represented 18.9% of the sample. The two smallest 
categories were the 75 and over (15.5%) and the 65–74 (7.3%). The sample was 
predominantly White (95.1%). Blacks and other races accounted for less than 5% of the 
sample. 
Most of the individuals [91.2% (n = 352)] treated with naloxone by the EMS first 
responders in this study experienced only one opioid overdose. The remaining individuals 
[8.8% (n = 34)] had frequencies of repeat opioid overdose events that ranged from one to 
three. The dose of naloxone administered by the professional first responders during the 
overdose events ranged from 0.5 mg to 8.0 mg per overdose dispatch. The mean dose was 





Characteristics of Study Sample 
Characteristics Dispatches involving naloxone 
administration (N = 386) 
Gender, no. (%)  
 Male  213 (55.2) 
 Female  173 (44.8) 
Age, no. (%)  
 15–24  36 (9.3) 
 25–34  91 (23.6) 
 35–44  73 (18.9) 
 45–54  73 (18.9) 
 55–64  60 (15.5) 
 65–74  28 (7.3) 
 75 and over  25 (6.5) 
 Mean, years  45.3 
 Median, years  44.0 
 Range, years  15–99 
Race, no. (%)  
 White  367 (95.1) 
 Black  13 (3.3) 
 Other  6 (1.6) 
Repeat overdose, no. (%)  
 0 repeat overdoses  352 (91.2) 
 1 repeat overdose  26 (6.7) 
 2 repeat overdoses  7 (1.8) 
 3 repeat overdoses  1 (.3) 
Naloxone dose, mg  
 Mean ± SD  1.80 ± .98 
 Median  2.0 
 Range  0.5–8.0 





Descriptive Statistics – Sample 2 
The size of the second sample was 156, which represented the weeks of the time 
frame from January 2017 through December 2019. During this time frame, 674 naloxone 
kits were distributed, and there were 77 repeat overdose events. 
Figure 6 shows that there were 30 occurrences (i.e., weeks) of naloxone 
distributions during the 3-year study period, with as many as 117 kits distributed in a 
single week. One repeat opioid overdose event occurred in 53 of the weeks, and two 
repeat events occurred in 12 of the weeks. There were no repeat events recorded in 91 of 
the weeks. Compared to the prior year, the number of weeks with repeat opioid overdose 
events increased in 2018 but decreased in 2019. There were 23, 24, and 18 weeks with 
repeat opioid overdose events in 2017, 2018, and 2019, respectively. An analysis of the 
naloxone distributions and the repeat opioid overdose events during the 3-year 
observation period indicated that there was no discernable pattern of association between 
the two measures. In other words, there were no definitive periods of increases or 





Figure 6. Repeat opioid overdose events and naloxone kits distributed by week (January 
2017 to December 2019). 
 
Figure 7 depicts the same data used to generate Figure 6, but the data were 
aggregated by month to provide a different perspective of the data. A logarithmic line 
graph was used to accommodate the full range of the quantities of the naloxone kits that 
were distributed during the study period. A visual examination of the descriptive data 





Figure 7. Repeat opioid overdose events and naloxone kits distributed by month (January 
2017 to December 2019). 
 
Statistical Assumptions 
Multiple logistic regression. Research Questions 1 through 4 were assessed 
using multiple logistic regression. The accuracy of the statistical test in predicting the 
odds of the dependent variable on the measures of the independent variable depends on 
the adherence to assumptions. The assumptions are that (a) there is only one dichotomous 
dependent variable, (b) the categories of the dependent variable are independent of each 
other, (c) there are one or more independent variables that are measured on the 
continuous or nominal scale, (d) the independent variables are not too correlated to each 
other (i.e., the absence of multicollinearity), (e) the relationship between the independent 
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variable and the logit (or log odds) of the dependent variable is linear, and (f) the 
predicted model is consistent with the measured outcome data (Warner, 2013). 
The dependent variable, repeat opioid overdose, was measured at the nominal 
level and had only two categories in which the observations could fall, which satisfied the 
first two assumptions. Four independent variables were included in the multiple logistic 
regression analysis: gender (a nominal, dichotomous variable), age (an ordinal variable 
with eight levels), race (a nominal variable with three categories), and the naloxone dose 
administered by professional first responders (a continuous variable). The independent 
variables with their respective levels of measurement satisfied the third assumption. 
In evaluating the multicollinearity assumption, SPSS was used to conduct cross-
tabulation tests of independence between the three categorical independent variables. A 
chi-square (or Pearson’s chi-square) test or a Fisher’s exact test can be used to examine 
the association or relationship between categorical variables in a cross-tabulation analysis 
(McHugh, 2013). A Cramer’s V test is used to measure of effect size of the association 
between variables. A Fisher’s exact test produces a statistic that tends to be more precise 
than the statistic produced by a chi-square test, but unlike a chi-square test, the Fisher’s 
exact test can only be used for 2-by-2 (or 2 x 2) cross-tabulation tables (McHugh, 2013). 
A chi-square test assumes that at least five observations (or counts) are in the expected 
cells of the cross-tabulation process (McHugh, 2013). If the assumption cannot be met, 
then a Fisher’s Exact test must be used instead (McHugh, 2013). The chi-square test, 
Fisher’s exact test, and Cramer’s V test are statistical procedures within SPSS. The results 
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Test of Independence Between Categorial Predictor Variables 
Cross tabulation tables Statistical test Value df Sig. 
Gender x Age Chi-square 13.75 6 .03  
Cramer's V .19  .03  
Gender x Race Chi-square .08 2 .96  
Fisher's exact .21  1.00  
Race x Age Chi-square 5.64 12 .93  
Fisher's exact 4.92  .98  
 
In a test of independence between predictor variables, the variables are 
independent of each other if the p value of the test statistic is greater than the acceptance 
level of significance (i.e., greater than .05). As indicated in Table 4, there was no 
statistically significant association between gender and race (p = 1.00) or between race 
and age (p = .98). The test of independence between gender and age was statistically 
significant, χ2 (6) = 13.75, p = .03, which meant that there was an association between 
these variables. The Cramer’s V statistic of this association was .19, which was indicative 
of a small (or low) association between gender and age as determined by Cohen’s (1988) 
effect size guidelines. A determination was made that the categorial variables of gender, 
age, and race were not too closely associated with each other, which satisfied the fourth 
assumption. 
The assumption regarding the linearity between the continuous independent 
variable (i.e., the naloxone dose administered by professional first responders) and the 
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logit of the dependent variable (i.e., repeat opioid overdose) was assessed using SPSS. A 
test statistic that is greater than the .05 level of statistical significance means that the 
independent variable is linearly related to the log odds of the dependent variable. Based 
on the p value of .84 of the Naloxone Dose x Ln-Naloxone Dose interaction term, the 
variable of the naloxone dose administered by first responders was linearly related to the 
log odds of the variable of repeat overdose, which satisfied the fifth assumption. 
The sixth assumption of whether the model predictions of outcomes in SPSS were 
consistent with the measured outcomes in the data was assessed using SPSS’s Hosmer-
Lemeshow goodness of fit (H-L) test. The null hypothesis of the H-L test is that the 
model is a good fit for predicting observed outcomes. The alternative hypothesis is that 
the model is poor (i.e., not a good fit) in predicting the observed outcomes (Warner, 
2013). A p value less than .05 means poor model predictions; therefore, a p value greater 
than .05 is preferred. The SPSS analysis yielded a p value of .33, which meant the model 
was a good fit for predicting the outcomes at an acceptable level. The sixth multiple 
logistic regression assumption was satisfied. 
Poisson regression. Poisson regression was used to answer Research Question 5. 
Adhering to Poisson regression assumptions is necessary to achieve valid research results 
that can be used to determine whether an independent variable has a significant effect on 
a dependent variable. The assumptions associated with Poisson regression require that (a) 
the dependent variable be represented by count data, (b) the observations on the 
dependent variable be independent of each other, (c) the mean and variance distributions 
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be equivalent, and (d) the counts demonstrate a Poisson distribution (Huang & Cornell, 
2012). 
 Count data were collected on the dependent variable (repeat opioid overdose) in 
Research Question 5, which satisfied the first assumption. The dependent variable was 
measured at the nominal level and had only two categories (i.e., yes and no). Because 
each observation could fall in only one of the two categories, the second assumption of 
independence was met. 
The final two Poisson regression assumptions were tested using SPSS. The 
descriptive statistics indicated that the mean and variance were .49 and .41, respectively. 
These values were similar and, therefore, satisfied the third assumption. 
The null hypothesis of the Kolmogorov-Smirnov test, which is a statistical test in 
the SPSS software, is that the dependent variable’s count data follow a Poisson 
distribution. The preferred statistic of the Kolmogorov-Smirnov test is one with a p value 
greater than the .05 acceptance level of significance. The SPSS test yielded a 
Kolmogorov-Smirnov test statistic of .34 with a p value of 1.00, which meant that the 
repeat opioid overdose count data followed a Poisson distribution. The fourth assumption 
was satisfied. 
Statistical Analysis Findings 
The results of the multiple logistic regression analysis that was conducted to 
answer Research Questions 1 through 4 are displayed in Table 5. The full predictive 
model was not statistically significant, χ2(10) = 15.82, p = .11. The Cox and Snell’s R2 = 
.04 and Nagelkerke’s R2 = .09 indicated that the variables of gender, age, race, and the 
106 
 
naloxone dose administered by first responders were weak predictors of repeat opioid 
overdose and accounted for only 4% and 9%, respectively, of the variance in the 
dependent variable. The results of the Poisson regression analysis that was conducted to 
answer Research Question 5 are displayed in Table 6. The full predictive model, 




Multiple Logistic Regression Analysis of Predictor Variables on Repeat Opioid Overdose 





Gender (female) -1.00 .43 5.54 1 .02 .37  .16  .85  
Age   1.92 6 .93       
25–34  -.08 .65 .02 1 .90 .92  .26  3.28  
35–44 .17 .66 .07 1 .80 1.18  .33  4.28  
45–54 -.13 .69 .04 1 .85 .88  .23  3.40  
55–64 -.73 .80 .83 1 .36 .48  .10  2.32  
65–74 .24 .83 .08 1 .78 1.27  .25  6.39  
75 and over -18.82 7869.35 .00 1 1.00 .00  .00  .  
Race   .73 2 .70       
Black .70 .82 .73 1 .39 2.02  .40  10.10  
Other -18.88 15989.35 .00 1 1.00 .00  .00  .  
Naloxone dose .11 .18 .41 1 .52 1.12  .79  1.59  
Constant (intercept) -2.07 .62 11.09 1 .00 .13    
Note. B = regression coefficient; SE = standard error; df = degrees of freedom; Sig. = 






Poisson Regression Analysis of Naloxone Kits Distributed on Repeat Opioid Overdose 
Parameter B SE 
Wald 
chi-square df Sig. Exp(B) 
95% CI 
Lower Upper 
(Intercept) -.71 .12 35.49 1 .00 .49 .39 .62 
Naloxone kits distributed .00 .01   .00 1 .97 1.00 .99 1.01 
Note. Dependent variable: Repeat overdose events; B = regression coefficient; SE = 
standard error; df = degrees of freedom; Sig. = significance; Exp(B) = exponential of 
B; CI = confidence interval. 
 
Research Question 1. What is the association between age and repeat opioid 
overdose? 
H01: There is no statistically significant association between age and repeat opioid 
overdose. 
Ha1: There is a statistically significant association between age and repeat opioid 
overdose. 
Six dummy variables represented the variable of age, and the 15–24 age category 
was set as the reference category in the multiple logistic regression analysis. As indicated 
in Table 5, those in the 65–74 and 35–44 age categories had the highest odds ratios. The 
odds of repeat opioid overdose among those 65–74 were 1.27 times the odds of repeat 
opioid overdose in the 15–24 category, and the odds of repeat opioid overdose among 
those 35–44 were 1.18 times the odds of repeat opioid overdose in the 15–24 age 
category. In other words, those individuals who were 65–74 years of age and 35–44 years 
of age were 27% and 18%, respectively, more likely to experience a repeat opioid 
overdose than those individuals who were 15–24 years of age. The odds of repeat opioid 
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overdose of those in the 25–34, 45–54, and 55–64 age categories were .92, .88, .48, 
respectively, times the odds of repeat opioid overdose of the reference group, which 
meant that those individuals were 8%, 12%, 52%, respectively, less likely to experience a 
repeat opioid overdose than those in the 15–24 age category. The odds ratio of those 
individuals in the 75 and older age category was close to zero, which meant that they 
were less likely to experience a repeat opioid overdose than those in the 15–24 age 
category. The odds ratios of all age categories had p values greater than the .05 level of 
significance, which meant that the null hypothesis was not rejected. There was no 
statistically significant association between age and repeat opioid overdose. In other 
words, age was not a significant predictor of repeat opioid overdose. 
Research Question 2. What is the association between gender and repeat opioid 
overdose? 
H02: There is no statistically significant association between gender and repeat 
opioid overdose. 
Ha2: There is a statistically significant association between gender and repeat 
opioid overdose. 
Table 5 indicates that the odds of repeat opioid overdose among females were .37 
times the odds of repeat opioid overdose among males, which meant that the odds 
decreased. Females in the sample were 63% less likely to experience a repeat opioid 
overdose than males. The odds ratio’s p value of .02 was less than the .05 level of 
significance; therefore, the null hypothesis was rejected, and the alternative hypothesis 
was accepted. There was a statistically significant association between gender and repeat 
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opioid. In other words, gender was a significant predictor of repeat opioid overdose. The 
95% CI [.16, .85] meant that in 95 out of 100 samples, the odds ratio could be as low as 
.16 and as high as .85. 
Research Question 3. What is the association between race and repeat opioid 
overdose? 
H03: There is no statistically significant association between race and repeat 
opioid overdose. 
Ha3: There is a statistically significant association between race and repeat opioid 
overdose. 
The variable of race was represented by two dummy variables, with the White 
race set as the reference category. As displayed in Table 5, the odds of repeat opioid 
overdose among Blacks were 2.02 times the odds of repeat opioid overdose among 
Whites. Blacks were 102% more likely to experience a repeat opioid overdose than 
Whites. All race categories had p values that were greater than the .05 level of 
significance, which meant that the odds ratios were not statistically significant. The null 
hypothesis was not rejected, which indicated that there was no statistically association 
relationship between age and repeat opioid overdose. In other words, age was not a 
significant predictor of repeat opioid overdose. 
Research Question 4. What is the association between the naloxone dose 




H04: There is no statistically significant association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose. 
Ha4: There is a statistically significant association between the naloxone dose 
administered by professional first responders during opioid overdose events and repeat 
opioid overdose. 
As indicated in Table 5, the variable of the naloxone dose administered had an 
odds ratio of 1.12, which meant that for every 1 mg increase in the naloxone dose, the 
odds of repeat opioid overdose increased by a factor of 1.12. In other words, the odds of 
repeat opioid overdose increased by 12% for every 1 mg increase in the naloxone dose. 
The p value of the odds ratio was .52, which was not statistically significant. The null 
hypothesis was not rejected, which meant that there was not a statistically significant 
association between the naloxone dose administered and repeat opioid overdose. The 
dose of naloxone administered by professional first responders was not a significant 
predictor of repeat opioid overdose. 
Research Question 5. What is the association between the distribution of 
naloxone rescue kits and repeat opioid overdose? 
H05: There is no statistically significant association between the distribution of 
naloxone rescue kits and repeat opioid overdose. 
Ha5: There is a statistically significant association between the distribution of 




An odds ratio of 1 means there is no association between the dependent and 
independent variables (Daniel & Cross, 2013). As displayed in Table 6, the odds ratio of 
naloxone kits distributed was 1.00, which meant there would not have been an 
association between repeat opioid overdose and the naloxone kits distributed had the odds 
ratio been statistically significant. The odds ratio’s p value of .97 exceeded the .05 level 
of significance, and the null hypothesis was not rejected. The distribution of naloxone 
kits was not a significant predictor of repeat opioid overdose. 
Summary 
Multiple logistic regression was used to analyze the relationship between the 
independent variables of gender, age, race, and the naloxone dose administered by 
professional first responders and the dependent variable of repeat opioid overdose. The 
predictive model was not statistically significant, and the independent variables were 
weak predictors of the dependent variable. Gender was the only independent variable that 
had a significant association with repeat opioid overdose. Females in the sample were or 
67% (p = .02) less likely to experience a repeat opioid overdose compared to the males in 
the sample. 
Poisson regression was used to analyze the relationship between the independent 
variable of the distribution of naloxone kits and the dependent variable of repeat opioid 
overdose. The predictive model was not statistically significant. The distribution of 
naloxone kits was not a significant predictor of repeat opioid overdose. 
The interpretations of these findings and the limitations that may affect the 
interpretations of these findings are discussed in Chapter 5. Implications for positive 
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social change and recommendations for future research regarding the accessibility of 
naloxone and repeat opioid overdose are addressed in Chapter 5 as well. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Quelling the morbidity and mortality associated with opioid dependence, abuse, 
and overdose remains a significant focus of public health authorities. A multifaceted 
approach, including increasing access to naloxone, is necessary to effectively address the 
problem (Rudd et al., 2016). This quantitative, correlational study with a cross-sectional 
design was conducted to determine the relationship between demographics, naloxone 
accessibility, and repeat opioid overdose in a Tennessee county. There is a paucity of 
research evidence that links the accessibility of naloxone with continued risky use 
behaviors by opioid users, particularly whether those individuals rely on naloxone as a 
safety net to revive them if they overdose (Rudski, 2016). The intent of this study was to 
expand the literature regarding what is known about the role of naloxone as an enabler in 
such behavior. 
The results of this current study indicated that there was a statistically significant 
association between gender and repeat opioid overdose. There was no statistically 
significant relationship between repeat opioid overdose and the independent variables of 
age, race, the distribution of naloxone kits, and the naloxone dose administered by 
professional first responders during opioid overdose events. This chapter includes the 
interpretation of the findings presented in Chapter 4. Discussions of the limitations of the 
study and recommendations for future research are also presented. Finally, implications 
for positive social change are examined, followed by a conclusion of the study. 
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Interpretation of the Findings 
Repeat Opioid Overdose Analysis 
Recent studies support the notion that the first nonfatal opioid overdose is often 
the precursor to repeat overdose. Of the opioid overdose cases treated with naloxone by 
the EMS responders in this current study, 8.8% represented repeat events, and 2.1% had 
two or more repeat events. The statistics were similar to those observed by Lasher et al. 
(2019), which indicated that 13.2% of the patients had a previous opioid overdose, and 
2.6% had two or more previous events. The statistics were also similar to those reported 
by Ray et al. (2018) in their 6-year study of EMS naloxone administration outcomes. Ray 
et al. found that 9.1% of the patients had at least one repeat opioid overdose, and 2.4% 
had at least two repeat opioid overdoses. 
Contrastingly, the repeat events observed in the current study were lower than 
those observed by Klebacher et al. (2017), who found that 27.2% of the patients treated 
with naloxone by EMS first responders had experienced a prior opioid overdose. Various 
factors could account for the difference in the results, but an obvious factor was the 
sample size difference. Klebacher et al. used a sample of 2,166 patients, which was over 
five and a half times greater than the sample size in this current study (N = 386). 
Demographics Analysis 
A review of the literature indicated that the demographic variables of age, gender, 
and race were rarely studied as predictors of repeat opioid overdose. Relevant studies 
contained analyses of the variables in which only descriptive statistics were applied. One 
study, in which the variables were assessed as predictors, was conducted recently by 
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Lowder, Amlung, and Ray (2020). Lowder et al. (2020) analyzed race, gender, and age as 
individual-level predictors of repeat nonfatal opioid overdose and fatal opioid overdose. 
Lowder et al. found that gender was a statistically significant predictor of repeat opioid 
overdose in that males were more likely to experience a repeat overdose compared to 
females (OR = .86, p < .001). Older age groups (i.e., 35–44, 45–54, 55–64, 65–74, 75–84, 
and 85 and older) were significantly less likely to experience a repeat overdose compared 
to the 15–24 age group, but race was not a significant predictor (Lowder et al., 2020). 
Consistent with the findings from Lowder et al. (2020), the current study 
indicated a statistically significant higher likelihood of repeat opioid overdose among 
males compared to females and that race was not a significant predictor of repeat opioid 
overdose. Unlike Lowder et al.’s study, however, the results of the current study did not 
indicate a significant association between the variables of age and repeat opioid overdose. 
Various factors could account for the difference in the studies’ results, including 
variations in the designs of the studies, behaviors of the populations, sample sizes, and 
unidentified confounders. 
Naloxone Administrations Analysis 
Outcomes associated with the administration of naloxone by EMS first responders 
have been documented in several studies. Lindstrom et al. (2015) compared the frequency 
of naloxone administrations by EMS providers to emergency department data to 
determine whether the prehospital administrations of naloxone were indicators of 
community opioid overdoses. Faul et al. (2017) evaluated national-level EMS data to 
assess the number of naloxone administrations during an opioid overdose rescue by EMS 
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first responders. Ray et al. (2018) used county EMS naloxone administration data to 
study opioid overdose mortality among patients with a recent nonfatal opioid overdose. 
Cash et al. (2018) also used national-level EMS data in an examination of annual 
naloxone administration frequencies and opioid-related mortality rates. In a recent study, 
Ashburn et al. (2020) evaluated the long-term mortality associated with EMS-provided 
naloxone. None of these studies or others reviewed in the literature focused on the dose 
of naloxone administered by EMS professionals as a predictor of a repeat opioid 
overdose. In that respect, the current study was novel. 
In the current study, the average dose of naloxone administered to a patient by 
EMS first responders during an opioid overdose dispatch was 1.8 mg. The finding was 
similar to that observed by Heavey, Delmerico, et al. (2018) who found that 1.76 mg of 
naloxone was the average dose administered by professional first responders (i.e., police 
officers and firefighters). The result was also similar to the mean dose of 2.7 mg of 
naloxone administered by EMS responders per opioid overdose observed by Lasher et al. 
(2019). The logistic regression analysis in the current study suggested that the odds of 
repeat opioid overdose increased, albeit slightly, as the dose of naloxone administered by 
EMS first responders increased (OR = 1.12). The finding, however, was not statistically 
significant, p = .52. Nevertheless, further research on the topic is recommended. Perhaps 




Naloxone Distribution Analysis 
Research involving community-based naloxone programs, like the one addressed 
in the current study, has been conducted to examine outcomes associated with such 
programs. For instance, the quantities of naloxone refills and overdose reversals among 
community-based programs were the outcomes studied by Rowe et al. (2015). Walley et 
al. (2013) focused on opioid-related death rates associated with the programs as the 
outcome. Additionally, Bagley et al.’s (2018) outcomes of interest included a 
characterization of family members who accessed community naloxone distribution 
programs, the types of community naloxone programs the families accessed, and the 
rescues performed by the family members. Neither of these studies nor others reviewed in 
the literature included an analysis of repeat opioid overdose as the outcome variable 
associated with the implementation of the community-based naloxone program. In that 
respect, the current study was novel. 
This study’s results indicated no statistically significant relationship between the 
distribution of naloxone kits through a community-based naloxone program and repeat 
opioid overdose. A determination of whether naloxone access—using naloxone 
distributions through a community-based program as a proxy—was a predictor of repeat 
opioid overdose could not be substantiated by the results of this study. The study’s 
inability to demonstrate a statistically significant finding regarding the role of the 
naloxone distribution program in the repeat opioid overdose phenomenon was not 
expected. Nevertheless, the study’s finding has value in that it provides a basis for 
subsequent research on the topic. The use of a larger sample size or a different 
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population, location, or method of measuring naloxone accessibility may yield a different 
result that is statistically significant. 
Theoretical Framework Analysis 
The diffusion of innovations theory was the theoretical framework used to 
develop and conduct this study. The main emphasis of the theory is diffusion, which 
Rogers (2003) described as the process by which something new (i.e., an item or idea) is 
perceived and communicated over time among a group of people. The theory is premised 
on the interplay of four elements: the innovation, a communication system, time, and a 
social system of people and organizations (Rogers, 2003). In the current study, naloxone 
was the innovation, the community-based naloxone program was the venue through 
which the importance of naloxone was communicated, the progression of naloxone use 
(measured by the distribution of naloxone kits and EMS-administered naloxone) was the 
representation of time, and the county observed in this study was the social system. 
The diffusion of innovations theory is instrumental in helping to understand 
behavioral changes in people, particularly how well an innovation is adopted and spread 
among society members (Rogers, 2003). The theory is also beneficial in understanding 
that there could be consequences associated with the adoption of an innovation (Rogers, 
2003). Examining the progression of naloxone accessibility over time and the nature of 
repeat opioid overdose as a potential consequence of this accessibility was the aim of this 
study. Given the aim, the diffusion of innovations theory was befitting as the framework. 
One finding of this study suggested that the odds of a repeat opioid overdose 
might increase with naloxone doses. The finding, however, was not statistically 
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significant. Another finding of the study indicated that the distribution of naloxone rescue 
kits did not have a statistically significant influence on the observed repeat opioid 
overdose events. The comparison of the results of this study to the results of similar 
studies was limited. The search of the literature did not yield any quantitative studies that 
addressed how access to naloxone affected opioid use behavior regarding repeat 
overdose. Only a qualitative study conducted by Heavey, Chang, et al. (2018) was found 
that addressed the topic. Heavey, Chang, et al. found that some participants contemplated 
naloxone availability when seeking to amplify their drug high by increasing their heroin 
dose. 
An application of the finding from Heavey, Chang, et al. (2018) could be 
extended to the current study. For instance, a significant increase in the repeat opioid 
overdose events following the distribution of naloxone kits might have suggested an 
increase in the adoption of naloxone use, particularly among sensation seekers. Sensation 
seekers are individuals who rely on the medication as a safety net as they venture to 
increase the dose of their opioid of choice (Heavey, Chang, et al., 2018). On the other 
hand, a significant decrease in the repeat opioid overdose events following the 
distribution of the kits also might have suggested an increased in the adoption of 
naloxone use, but for a different reason. The notifications to EMS first responders 
regarding an opioid overdose event might have been displaced by naloxone rescues 
performed by bystanders (i.e., family members or friends of the overdose victim) who 
chose not to notify the EMS, a phenomenon described by Keane et al. (2018). In both 
scenarios, the influence of confounding, mediating, or moderating factors would be 
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considered as potential explanations as well. Neither scenario, however, was manifested 
by the results of this current study. Therefore, the process of innovation adoption 
described in the diffusion of innovations theory was not supported by the results of this 
current study. 
Limitations of the Study 
The intent of this study was to contribute to the literature regarding what is known 
about the impact of naloxone on opioid use behavior. The results, which were subject to 
several limitations, should be interpreted with caution. The first limitation was that the 
correlational design used in this study was observational, which meant the findings did 
imply a causal effect. Contributing to the design limitation was the inability to identify 
and include every variable in the study that could have been an effect modifier or 
confounder. 
Second, the measure of repeat opioid overdose was based solely on data from the 
county EMS, which was necessitated by the inability to access the medical records of the 
patients treated by the county EMS first responders. In the absence of such information, 
confirming each repeat overdose case or determining whether a patient suffered from a 
substance use disorder or other conditions that might have contributed to the emergency 
event was infeasible. The measure of repeat opioid overdose could have been overstated 
and could have biased the study results. Alternatively, the repeat opioid overdose cases 
were just as likely underestimated. Not all of the opioid overdoses in the sampling frame 
required the administration of naloxone. In many instances, the overdose events involved 
the use of oxygen—a standard of care practice when patients are not breathing (Banta-
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Green et al., 2017)—or other medications as the method of treatment rather than 
naloxone. Despite the limitation, the use of EMS data offered the advantage of being 
timesaving and cost-effective because the data were already collected and easier to search 
and analyze than reviewing numerous hospital charts from multiple hospitals (see 
Lindstrom et al., 2015). 
A third limitation, which was linked to the second limitation, was potential 
misclassification bias. Lasher et al. (2019) discussed the importance of accurately 
assessing the rescue situation to ensure the administration of naloxone only when 
warranted, which can minimize the bias. There could have been misclassifications of an 
emergency rescue as an opioid overdose when it was not. However, the potential was less 
likely because the rescue efforts by the county’s EMS first responders were governed by 
prescribed state EMS protocols and guidance from the local EMS medical director. 
Additionally, adequately defined variables were incorporated in this study to mitigate the 
concern of misclassification bias. 
A fourth limitation involved the measure of naloxone accessibility. The measure 
was limited to the distribution of naloxone rescue kits and the administration of naloxone 
by the county’s EMS first responders. Local pharmacies, emergency departments, and 
clinics are other venues that provide naloxone to patients. These venues, however, were 
not part of the scope of this study. A related limitation was the limited amount of data 
available from the community-based naloxone program. Naloxone and the related 
training had only been provided through the program in the county since November 2017. 
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There were several extended periods (i.e., months) where no kits were distributed, which 
likely affected the statistical analysis. 
Finally, the data were collected and analyzed on a single county in the state. The 
study’s small scale and geographical specificity limited the generalizability of the results 
to larger populations. 
Recommendations 
Part of the rationale for using the diffusion of innovations theory as a framework 
for the current study was the theory’s emphasis on unanticipated consequences that might 
occur with the adoption of an innovation. The phenomenon of repeat opioid overdose was 
the outcome variable examined as a potential unanticipated consequence of efforts to 
improve naloxone’s accessibility (i.e., the innovation) and reduce opioid overdose 
mortality. A quantitative approach was used to help address the lack of quantitative 
studies in the literature in which the phenomenon has been explored. 
Although the current study did not indicate a statistically significant association 
between repeat opioid overdose and the measure of naloxone accessibility, the study may 
inform the design of future research conducted to examine the relationship. A mixed-
methods approach is recommended because the qualitative aspect of the design may 
provide contextual information regarding the repeat opioid overdose events. Also, an 
observation period longer than 3 years is recommended. A long-range approach allows 




Although a true accounting of repeat opioid overdoses may never be known, the 
incorporation of data from other sources may help quantify the elusive statistic. 
Community LEOs represent such a source. The expansion of naloxone access efforts has 
included equipping LEO first responders with rescue naloxone (NCHRC, n.d.). The 
LEOs often arrive at emergency scenes involving an opioid overdose and administer 
naloxone before EMS responders arrive (Davis et al., 2015). Family members and friends 
of individuals who use opioids—either licitly or illicitly—represent another data source. 
Naloxone access has been expanded to include family members and friends of opioid 
users because these laypersons are often first to witness the opioid overdose. Although 
the naloxone training requires calling 911 in addition to administering the medication, 
some laypersons do not call, which means many repeat opioid overdoses are likely 
undisclosed (Bagley et al., 2018). Additional sources of repeat opioid overdose data 
include emergency department visits and community medical examiner records. Future 
research should explore incorporating data from these sources to provide a 
comprehensive measure of repeat opioid overdose. 
Community-based naloxone programs represent only one venue that makes 
naloxone accessible to people who need it. The diffusion of the medication throughout a 
community via naloxone programs effectively reduces opioid-related mortality (Keane et 
al., 2018). In this study, naloxone access was restricted to data on the naloxone 
administrations by EMS first responders and data on the distribution of naloxone rescue 
kits by a singular community-based naloxone program. Health departments, medical 
clinics, hospital emergency departments, and pharmacies are other organizations that 
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provide the medication—in emergency and nonemergency conditions—to individuals 
who need it as well as to the families and friends of these individuals. Collecting data on 
naloxone dispensed via these organizations may provide a better measure of naloxone 
accessibility and, therefore, should be considered in future studies. 
Demographic information is important in helping public health practitioners 
understand the populations at risk of repeat opioid overdose. The sample used in the 
current study was smaller than other relevant studies in the literature and lacked racial 
diversity. The demographic variables included in this study (particularly race and age) 
and their relationship to repeat opioid overdose warrant further research. The research 
should include the use of data from a larger, racially diverse county or the use of 
statewide data. 
Implications 
Providing naloxone to laypersons and training them to recognize and to respond 
to an opioid overdose are public health efforts aimed at reducing opioid-related mortality 
(McDonald & Strang, 2016). Such efforts create opportunities to link individuals with 
substance use disorders to treatment programs (Vivolo-Kantor et al., 2018). J. D. Jones et 
al. (2017) discussed that the provision of naloxone to people known to abuse drugs is 
often critically scrutinized as a potential contributor to compensatory drug use. Some 
people believe that providing naloxone to individuals who misuse drugs such as opioids 
may cause them to engage in riskier drug behaviors. 
Perhaps the opposition to increasing the public’s access to naloxone stems from a 
belief that all individuals suffering from opioid use disorder can quit using opioids at any 
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time. What is often misunderstood or unknown is that opioid use disorder involves the 
addiction to opioids, which is a disease that is chronic and recurring (Leshner, 1997). 
Individuals who use opioids for long periods tend to experience a reduction in the brain’s 
functional connectivity and a volumetric loss of the amygdala, which is responsible for 
the recognition of fear and social judgment (Rasia-Filho, Londero, & Achaval, 2000; 
Upadhyay et al., 2010). Discontinuing the use of the opioids may be beyond the self-
efficacy of many individuals. Ready access to naloxone may help save the lives of these 
individuals until they receive substance use treatment. 
Research indicates that opioid overdoses that are nonfatal are often precursors to 
repeat overdoses, which are associated with opioid overdose mortality (Olfson et al., 
2018; Ray et al., 2018). The relationship between naloxone use and repeat overdoses 
involving opioids has rarely been explored. Positive or negative consequences of 
naloxone adoption were not evident in the results of the current study as was expected in 
accordance with the diffusion of innovations theory. A follow-up search of the literature 
revealed a recent study in which the relationship was explored. Ashburn et al. (2020) 
examined the 1-year mortality associated with patients revived with naloxone by EMS 
first responders. Ashburn et al. found that of the 72.2% (n = 2,244) overdose patients 
with improved conditions after being administered naloxone by the EMS professionals, 
12.0% of the patients were dead within 1 year. Of the patients who died, the mortality 
rates of the patients who were treated with naloxone during one, two, and three or more 
overdose events were 13.0% (n = 234/1,804), 11.5% (n = 17/148), and 6.8% (n = 3/44), 
respectively (Ashburn et al., 2020). 
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 The repeat opioid overdose statistics from Ashburn et al. (2020) and from this 
current study provide further evidence that the opioid overdose crisis remains an urgent 
problem in need of an expeditious solution. Overdoses involving opioids claim the lives 
of over 47,000 people in the United States each year (Scholl et al., 2019). According to 
Chen et al. (2019), the annual opioid-related mortality in the United States is projected to 
reach 82,000 by 2025. The findings of the current study may help prevent the projected 
statistic. 
The use of local data was a strength of this study. Such data are crucial in 
developing of community programs aimed at prevention (Madah et al., 2017). The 
administrators of the community-based naloxone program may use the results of this 
study to gauge the effectiveness of their program. Other public health practitioners may 
use the findings to assess the prevalence of repeat opioid overdose within the community 
and to design and implement prevention and intervention programs. Clinicians and 
pharmacists may use the findings to improve their awareness of naloxone access policies 
and legislation. The clinicians and pharmacists may also use the findings to help identify 
patients at risk opioid overdose (and repeat opioid overdose) and to help educate these 
patients about opioids and naloxone. The local EMS first responders may use the findings 
for program evaluation purposes. This study provided statistics on repeat opioid overdose 
and on the characteristics of the opioid overdose patients. Such information may be 
useful to EMS first responders in evaluating the effectiveness of their protocols used to 
identify and treat opioid overdose patients. Finally, this study may be used as a reference 
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source to help educators and the media inform community members about opioid 
overdose and naloxone. 
Conclusion 
Naloxone saves lives. Community-based naloxone education and distribution 
programs are valuable in helping the public understand, recognize, and respond to opioid 
overdoses using naloxone rescue kits. The broad distribution of naloxone to the general 
public is not without controversy. The long-term effects of the medication’s accessibility 
on opioid use behaviors are yet to be determined. More research, particularly of a 
quantitative nature, is needed to help understand the relationship. This study was 
conducted to provide such information. 
Consistent with the literature, this study indicated a statistically significant 
association between gender and repeat opioid overdose. Among the participants in the 
study, males were more likely to experience repeat opioid overdose compared to females. 
Unlike many studies in the literature, this study indicated that the association between the 
predictor variables of age and race and the outcome variable of repeat opioid overdose 
was not statistically significant. Additionally, there was not a significant association 
between naloxone accessibility (i.e., as measured by the distribution of naloxone kits and 
administration of naloxone by EMS first responders) and repeat opioid overdose. The 
finding does not mean that a relationship between naloxone accessibility and repeat 
opioid overdose does not exist, only that the design, methods, and sample used in this 
study were unable to detect an association that was statistically significant. In light of this 
finding, further research aimed at exploring the relationship between naloxone 
128 
 
accessibility and repeat opioid overdose is warranted. This study can serve as the basis 
for such research. 
The loss of 47,000 U.S. lives each year to opioid-related overdose (Scholl et al., 
2019) is preventable. Finding a solution to the current opioid crisis will require a 
concerted effort from contributors such as policy makers, health and public health 
practitioners, researchers, local communities, and law enforcement professionals. As 
suggested by Wheeler et al. (2012), such comprehensive measures must include 
educating the public and health care practitioners, strengthening the guidelines for 
prescribing and monitoring prescription opioids, and ensuring access to naloxone and 




Adams, J. (2018). Increasing naloxone awareness and use: The role of health care 
practitioners. Journal of the American Medical Association, 319(20), 2073–2074. 
doi:10.1001/jama.2018.4867 
ADAPT Pharma. (n.d.). What is Narcan® nasal spray? Retrieved from 
https://www.narcan.com/ 
Alexander, M. J., Kiang, M. V., & Barbieri, M. (2018). Trends in black and white opioid 
mortality in the United States, 1979–2015. Epidemiology, 29(5), 707–715. 
doi:10.1097/EDE.0000000000000858 
Althubaiti, A. (2016). Information bias in health research: Definition, pitfalls, and 
adjustment methods. Journal of Multidisciplinary Healthcare, 9, 211–217. 
doi:10.2147/JMDH.S104807 
American Society of Addiction Medicine. (2015). National practice guideline for the use 





Asamoah, M. K. (2014). Re-examination of the limitations associated with correlational 




Ashburn, N. P., Ryder, C. W., Angi, R. M., Snavely, A. C., Nelson, R. D., Bozeman, W. 
P., … Stopyra, J. P. (2020). One-year mortality and associated factors in patients 
receiving out-of-hospital naloxone for presumed opioid overdose. Annals of 
Emergency Medicine, 75(5), 559–567. doi:10.1016/j.annemergmed.2019.11.022 
Babbie, E. (2017). Basics of social research (7th ed.). Boston, MA: Cengage Learning. 
Bachyrycz, A., Shrestha, S., Bleske, B. E., Tinker, D., & Bakhireva, L. N. (2017). Opioid 
overdose prevention through pharmacy-based naloxone prescription program: 
Innovations in health care delivery. Substance Abuse, 38(1), 55–60. 
doi:10.1080/08897077.2016.1184739 
Bagley, S. M., Forman, L. S., Ruiz, S., Cranston, K., & Walley, A. Y. (2018). Expanding 
access to naloxone for family members: The Massachusetts experience. Drug and 
Alcohol Review, 37(4), 480–486. doi:10.1111/dar.12551 
Bagley, S. M., Peterson, J., Cheng, D. M., Jose, C., Quinn, E., O’Conner, P. G., & 
Walley, A. Y. (2015). Overdose education and naloxone rescue kits for family 
members of opioid users: Characteristics, motivations and naloxone use. Drug 
and Alcohol Dependence, 36(2), 149–154. doi:10.1080/08897077.2014.989352 
Banta-Green, C. J., Coffin, P. O., Schoeppe, J. A., Merrill, J. O., Whiteside, L. K., & 
Ebersol, A. K. (2017). Heroin and pharmaceutical opioid overdose events: 




Blanco, C., & Volkow, N. D. (2019). Management of opioid use disorder in the USA: 
Present status and future directions. Lancet, 393(10182), 1760–1772. 
doi:10.1016/S0140-6736(18)33078-2 
Bowles, J. M., & Lankenau, S. E. (2019). “I gotta go with modern technology, so I’m 
gonna give ‘em the Narcan”: The diffusion of innovations and an opioid overdose 
prevention program. Qualitative Health Research, 29(3), 345–356. 
doi:10.1177/1049732318800289 
Brady, J. E., Giglio, R., Keyes, K. M., DiMaggio, C., & Li, G. (2017). Risk markers for 
fatal and non-fatal prescription drug overdose: A meta-analysis. Injury 
Epidemiology, 4(1), 1–24. doi:10.1186/s40621-017-0118-7 
Campbell, D. T. (1957). Factors relevant to the validity of experiments in social 
settings. Psychological Bulletin, 54(4), 297–312. doi:10.1037/h0040950  
Carpenter, D. M., Dhamanaskar, A. K., Gallegos, K. L., Shepherd, G., Mosley, S. L., & 
Roberts, C. A. (2019). Factors associated with how often community pharmacists 
offer and dispense naloxone. Research in Social and Administrative Pharmacy, 
15(12), 1415–1418 doi:10.1016/j.sapharm.2018.07.008 
Cash, R. E., Kinsman, J., Crowe, R. P., Rivard, M. K., Faul, M., & Panchal, A. R. (2018). 
Naloxone administration frequency during emergency medical service events — 
United States, 2012–2016. MMWR. Morbidity and Mortality Weekly 
Report, 67(31), 850–853. doi:10.15585/mmwr.mm6731a2 
Centers for Disease Control and Prevention. (2018). Using naloxone to reverse opioid 
overdose in the workplace: Information for employers and workers (DHHS 
132 
 
(NIOSH) Publication Number 2019-101). Retrieved from 
https://www.cdc.gov/niosh/docs/2019-101/background.html 
Chakraborty, B., Maiti, R., & Strecher, V. J. (2018). The effectiveness of web-based 
tailored smoking cessation interventions on the Quitting Process (Project Quit): 
Secondary analysis of a randomized controlled trial. Journal of Medical Internet 
Research, 20(6), e213. doi:10.2196/jmir.9555 
Chen, Q., Larochelle, M. R., Weaver, D. T., Lietz, A. P., Mueller, P. P., Mercaldo, S., … 
Chhatwal, J. (2019). Prevention of prescription opioid misuse and projected 
overdose deaths in the United States. JAMA Network Open, 2(2), e187621. 
doi:10.1001/jamanetworkopen.2018.7621 
Chou, R., Korthuis, P. T., McCarty, D., Coffin, P. O., Griffin, J. C., Davis-O’Reilly, C., 
… Daya, M. (2017). Management of suspected opioid overdose with naloxone in 
out-of-hospital settings: A systematic review. Annals of Internal Medicine, 
167(12), 867–875. doi:10.7326/M17-2224 
Cohen J. (1988). Statistical Power Analysis for the Behavioral Sciences. New York, NY: 
Routledge Academic. 
Cohen, J. (1992). Statistical power analysis. Current Directions in Psychological Science, 
1(3), 98–101. doi:10.1111/1467-8721.ep10768783 




Compton, W. M., Jones, C. M., & Baldwin, G. T. (2016). Relationship between 
nonmedical prescription-opioid use and heroin use. New England Journal of 
Medicine, 374(2), 154–163. doi:10.1056/NEJMra1508490 
Cook, B. G., & Cook, L. (2016). Research designs and special education research: 
Different designs address different questions. Learning Disabilities Research and 
Practice, 31(4), 190–198. doi:10.1111/ldrp.12110 
Cor, M. K. (2016). Trust me, it is valid: Research validity in pharmacy education 
research. Currents in Pharmacy Teaching and Learning, 8(3), 391–400. 
doi:10.1016/j.cptl.2016.02.014 
Crawford, L. M., Burkholder, G. J., & Cox, K. A. (2016). Writing the research proposal. 
In Burkholder, G. J., Cox, K. A., & Crawford, L. M. (Eds.), The scholar-
practitioner’s guide to research design. Baltimore, MD: Laureate Publishing. 
Creswell, J. W. (2014). Research design: Qualitative, quantitative, and mixed methods 
approaches (4th ed.). Thousand Oaks, CA: SAGE Publications. 
Dahlem, C. H., King, L., Anderson, G., Marr, A., Waddell, J. E., & Scalera, M. (2017). 
Beyond rescue: Implementation and evaluation of revised naloxone training for 
law enforcement officers. Public Health Nursing, 34(6), 516–521. 
doi:10.1111/phn.12365 
Daniel, W. W. & Cross, C. L. (2013). Biostatistics: A foundation for analysis in the 
health sciences. Hoboken, NJ: Wiley. 
134 
 
Davis, C. S., & Carr, D. (2015). Legal changes to increase access to naloxone for opioid 
overdose reversal in the United States. Drug and Alcohol Dependence, 157, 112–
120. doi:10.1016/j.drugalcdep.2015.10.013 
Davis, C. S., & Carr, D. (2017). State legal innovations to encourage naloxone 
dispensing. Journal of the American Pharmacists Association, 57(2), S180–S184. 
doi:10.1016/j.japh.2016.11.007 
Davis, C. S., Carr, D., Southwell, J. K., & Beletsky, L. (2015). Engaging law 
enforcement in overdose reversal initiatives: Authorization and liability for 
naloxone administration. American Journal of Public Health, 105(8), 1530–1537. 
doi:10.2105/AJPH.2015.302638 
Davis, C. S., Ruiz, S., Glynn, P., Picariello, G., & Walley, A. Y. (2014). Expanded access 
to naloxone among firefighters, police officers, and emergency medical 
technicians in Massachusetts. American Journal of Public Health, 104(8), e7–e9. 
doi:10.2105/AJPH.2014.302062 
Dorey, F. J. (2011). In brief: Statistics in brief: Statistical power: What is it and when 
should it be used? Clinical Orthopaedics and Related Research, 469(2), 619–620. 
doi:10.1007/s11999-010-1435-0  
Dowell, D., Haegerich, T. M., & Chou, R. (2016, March 18). CDC guideline for 
prescribing opioids for chronic pain — United States, 2016. MMWR. 




du Prel, J.-B., Hommel, G., Roehrig, B., & Blettner, M. (2009). Confidence interval or p-
value? Part 4 of a series on evaluation of scientific publications. Deutsches 
Arzteblatt International, 106(19), 335–339. doi:10.3238/arztebl.2009.0335 
Erdfelder, E., Faul, F., & Buchner, A. (1996). GPOWER: A general power analysis 
program. Behavior Research Methods, Instruments and Computers, 28(1), 1–11. 
doi:10.3758/BF03203630 
Farrugia, A., Fraser, S., Dwyer, R., Fomiatti, R., Neale, J., Dietze, P., & Strang, J. (2019). 
Take-home naloxone and the politics of care. Sociology of Health and Illness, 
41(2), 427–443. doi:10.1111/1467-9566.12848 
Faul, M., Dailey, M. W., Sugerman, D. E., Sasser, S. M., Levy, B., & Paulozzi, L. J. 
(2015). Disparity in naloxone administration by emergency medical service 
providers and the burden of drug overdose in US rural communities. American 
Journal of Public Health, 105(Suppl. 3), e26–e32. 
doi:10.2105/AJPH.2014.302520 
Faul, M., Lurie, P., Kinsman, J. M., Dailey, M. W., Crabaugh, C., & Sasser, S. M. 
(2017). Multiple naloxone administrations among emergency medical service 
providers is increasing. Prehospital Emergency Care, 21(4), 411–419. 
doi:10.1080/10903127.2017.1315203 
Flannelly, K. J., Flannelly, L. T., & Jankowski, K. R. B. (2018). Threats to the internal 
validity of experimental and quasi-experimental research in healthcare. Journal of 
Health Care Chaplaincy, 24(3), 107–130. doi:10.1080/08854726.2017.1421019 
136 
 
Florence, C. S., Luo, F., Xu, L., & Zhou, C. (2016). The economic burden of prescription 
opioid overdose, abuse, and dependence in the United States, 2013. Medical Care, 
54(10), 901–906. doi:10.1097/MLR.0000000000000625 
Frankfort-Nachmias, C., & Leon-Guerrero, A. (2015). Social statistics for a diverse 
society (7th ed.). Thousand Oaks, CA: Sage Publications. 
Freeman, P. R., Hankosky, E. R., Lofwall, M. R., & Talbert, J. C. (2018). The changing 
landscape of naloxone availability in the United States, 2011–2017. Drug and 
Alcohol Dependence, 191, 361–364. doi:10.1016/j.drugalcdep.2018.07.017 
Gatewood, A. K., Van Wert, M. J., Andrada, A. P., & Surkan, P. J. (2016). Academic 
physicians’ and medical students’ perceived barriers toward bystander 
administered naloxone as an overdose prevention strategy. Addictive 
Behaviors, 61, 40–46. doi:10.1016/j.addbeh.2016.05.013 
George, A. J. T. (2016). Research ethics. Medicine, 44(10), 615–618. 
doi:10.1016/j.mpmed.2016.07.007 
Gunn, A. H., Smothers, Z. P. W., Schramm-Sapyta, N., Freiermuth, C. E., MacEachern, 
M., & Muzyk, A. J. (2018). The emergency department as an opportunity for 
naloxone distribution. Western Journal of Emergency Medicine, 19(6), 1036–
1042. doi:10.5811/westjem.2018.8.38829 
Guy, G. P., Jr., Zhang, K., Bohm, M. K., Losby, J., Lewis, B., Young, R., … Dowell, D. 
(2017). Vital signs: Changes in opioid prescribing in the United States, 2006–




Handal, K. A., Schauben, J. L., Salamone, F. R. (1983). Naloxone. Annals of Emergency 
Medicine, 12(7), 438–445. 
Haug, N. A., Bielenberg, J., Linder, S. H., & Lembke, A. (2016). Assessment of provider 
attitudes toward #naloxone on Twitter. Substance Abuse, 37(1), 35–41. 
doi:10.1080/08897077.2015.1129390 
Heavey, S. C., Chang, Y.-P., Vest, B. M., Collins, R. L., Wieczorek, W., & Homish, G. 
G. (2018). ‘I have it just in case’ — Naloxone access and changes in opioid use 
behaviours. International Journal of Drug Policy, 51, 27–35. 
doi:10.1016/j.drugpo.2017.09.015 
Heavey, S. C., Delmerico, A. M., Burstein, G., Moore, C., Wieczorek, W. F., Collins, R. 
L., … Homish, G. G. (2018). Descriptive epidemiology for community-wide 
naloxone administration by police officers and firefighters responding to opioid 
overdose. Journal of Community Health, 43(2), 304–311. doi:10.1007/s10900-
017-0422-8 
Holgado-Tello, F. P., Chacon-Moscoso, S., Sanduvete-Chaves, S., & Perez-Gil, J. A. 
(2016). A simulation study of threats to validity in quasi-experimental designs: 
Interrelationship between design, measurement, and analysis. Frontiers in 
Psychology, 7. doi:10.3389/fpsyg.2016.00897 
Huang, F. L., & Cornell, D. G. (2012). Pick your Poisson: A tutorial on analyzing counts 




Humphreys, K. (2015). An overdose antidote goes mainstream. Health Affairs, 34(10), 
1624–1627. doi:10.1377/hlthaff.2015.0934 
Jones, C. M., Logan, J., Gladden, R. M., & Bohm, M. K. (2015, July 10). Vital signs: 
Demographic and substance use trends among heroin users — United States, 




Jones, J. D., Campbell, A., Metz, V. E., & Comer, S. D. (2017). No evidence of 
compensatory drug use risk behavior among heroin users after receiving take-
home naloxone. Addictive Behaviors, 71, 104. doi:10.1016/j.addbeh.2017.03.008 
Kaminski, J. (2011). Diffusion of innovation theory. Canadian Journal of Nursing 
Informatics, 6(2). Retrieved from http://cjni.net/ 
Keane, C., Egan, J. E., & Hawk, M. (2018). Effects of naloxone distribution to likely 
bystanders: Results of an agent-based model. International Journal on Drug 
Policy, 55, 61–69. doi:10.1016/j.drugpo.2018.02.008 
Kim, D., Irwin, K. S., & Khoshnood, K. (2009). Expanded access to naloxone: Options 
for critical response to the epidemic of opioid overdose mortality. American 
Journal of Public Health, 99(3), 402–407. doi:10.2105/AJPH.2008.136937 
Kirson, N. Y., Scarpati, L. M., Enloe, C. J., Dincer, A. P., Birnbaum, H. G., & Mayne, T. 
J. (2017). The economic burden of opioid abuse: Updated findings. Journal of 
139 
 
Managed Care and Specialty Pharmacy, 23(4), 427–445. 
doi:10.18553/jmcp.2017.16265 
Klebacher, R., Harris, M. I., Ariyaprakai, N., Tagore, A., Robbins, V., Dudley, L. S., … 
Merlin, M. A. (2017). Incidence of naloxone redosing in the age of the new opioid 
epidemic. Prehospital Emergency Care, 21(6), 682–687. 
doi:10.1080/10903127.2017.1335818 
Koester, S., Mueller, S. R., Raville, L., Langegger, S., & Binswanger, I. A. (2017). Why 
are some people who have received overdose education and naloxone reticent to 
call Emergency Medical Services in the event of overdose? International Journal 
on Drug Policy, 48, 115–124. doi:10.1016/j.drugpo.2017.06.008 
Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L., Clark, T. W., & 
Alexander, G. C. (2015). The prescription opioid and heroin crisis: A public 
health approach to an epidemic of addiction. Annual Review of Public Health, 36, 
559–574. doi:10.1146/annurev-publhealth-031914-122957 
Kreek, M. J. (2002). Molecular and cellular neurobiology and pathophysiology of opiate 
addiction. In K. L. Davis, D. Charney, J. T. Coyle, L. M. Miller, & C. Nemeroff 
(Eds.), Neuropsychopharmacology: The fifth generation of progress (pp. 1491–
1506). New York: Lippincott Williams & Wilkins. 
Kwak, S. K., & Kim, J. H. (2017). Statistical data preparation: Management of missing 




Lambdin, B. H., Zibbell, J., Wheeler, E., & Kral, A. H. (2018). Identifying gaps in the 
implementation of naloxone programs for laypersons in the United 
States. International Journal of Drug Policy, 52, 52–55. 
doi:10.1016/j.drugpo.2017.11.017 
Larochelle, M. R., Liebschutz, J. M., Zhang, F., Ross-Degnan, D., & Wharam, J. F. 
(2016). Opioid prescribing after nonfatal overdose and association with repeated 
overdose: A cohort study. Annals of Internal Medicine, 164(1), 1–9. 
doi:10.7326/M15-0038 
Lasher, L., Rhodes, J., & Viner-Brown, S. (2019). Identification and description of non-
fatal opioid overdoses using Rhode Island EMS data, 2016–2018. Rhode Island 
Medical Journal, 102(2), 41–45. Retrieved from 
http://www.rimed.org/rimedicaljournal-current.asp 
Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science, 278(5335), 
45–47. doi:10.1126/science.278.5335.45 
Lewis, D. A., Park, J. N., Vail, L., Sine, M., Welsh, C., & Sherman, S. G. (2016). 
Evaluation of the overdose education and naloxone distribution program of the 
Baltimore student harm reduction coalition. American Journal of Public Health, 
106(7), 1243–1246. doi:10.2105/AJPH.2016.303141 
Lindstrom, H. A., Clemency, B. M., Snyder, R., Consiglio, J. D., May, P. R., & Moscati, 
R. M. (2015). Prehospital naloxone administration as a public health surveillance 




Lohr, S. L. (2010). Sampling: Design and analysis (2nd ed.). Boston, MA: Brooks/Cole 
Cengage Learning. 
Lowder, E. M., Amlung, J., & Ray, B. R. (2020). Individual and county-level variation in 
outcomes following non-fatal opioid-involved overdose. Journal of Epidemiology 
and Community Health, 74(4), 369–376. doi:10.1136/jech-2019-212915 
Madah, A. D., Clausen, T., Myrmel, L., Brattebø, G., & Lobmaier, P. (2017). 
Circumstances surrounding non-fatal opioid overdoses attended by ambulance 
services. Drug and Alcohol Review, 36(3), 288–294. doi:10.1111/dar.12451 
Marco, C. A., Trautman, W., Cook, A., Mann, D., Rasp, J., Perkins, O., & Ballester, M. 
(2018). Naloxone use among emergency department patients with opioid 
overdose. Journal of Emergency Medicine, 55(1), 64–70. 
doi:10.1016/j.jemermed.2018.04.022 
Martínez-Mesa, J., González-Chica, D. A., Duquia, R. P., Bonamigo, R. R., & Bastos, J. 
L. (2016). Sampling: How to select participants in my research study? Anais 
Brasileiros De Dermatologia, 91(3), 326–330. doi:10.1590/abd1806-
4841.20165254 
Mattson, C. L., O’Donnell, J., Kariisa, M., Seth, P., Scholl, L., & Gladden, R. M. (2018). 
Opportunities to prevent overdose deaths involving prescription and illicit 
opioids, 11 states, July 2016–June 2017. MMWR. Morbidity and Mortality Weekly 
Report, 67(34), 945–951. doi:10.15585/mmwr.mm6734a2 
McClellan, C., Lambdin, B. H., Ali, M. M., Mutter, R., Davis, C. S., Wheeler, E., … 
Kral, A. H. (2018). Opioid-overdose laws association with opioid use and 
142 
 
overdose mortality. Addictive Behaviors, 86, 90–95. 
doi:10.1016/j.addbeh.2018.03.014 
McCusker, K., & Gunaydin, S. (2015). Research using qualitative, quantitative or mixed 
methods and choice based on the research. Perfusion, 30(7), 537–542. 
doi:10.1177/0267659114559116 
McDonald, R., Campbell, N. D., & Strang, J. (2017). Twenty years of take-home 
naloxone for the prevention of overdose deaths from heroin and other opioids—
Conception and maturation. Drug and Alcohol Dependence, 178, 176–187. 
doi:10.1016/j.drugalcdep.2017.05.001 
McDonald, R., & Strang, J. (2016). Are take-home naloxone programmes effective? 
Systematic review utilizing application of the Bradford Hill 
criteria. Addiction, 111(7), 1177–1187. doi:10.1111/add.13326 
McHugh, M. L. (2013). The chi-square test of independence. Biochemia Medica, 23(2), 
143–149. doi:10.11613/bm.2013.018 
Mishra, P., Pandey, C. M., Singh, U., Gupta, A., Sahu, C., & Keshri, A. (2019). 
Descriptive statistics and normality tests for statistical data. Annals of Cardiac 
Anaesthesia, 22(1), 67–72. doi:10.4103/aca.ACA_157_18 
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010). Preferred reporting items 
for systematic reviews and meta-analyses: The PRISMA statement. International 
Journal of Surgery, 8(5), 336–341. doi:10.1016/j.ijsu.2010.02.007 
143 
 
National Highway Traffic Safety Administration. (2019). National EMS scope of practice 
model, 2019. Retrieved from 
https://www.ems.gov/pdf/National_EMS_Scope_of_Practice_Model_2019.pdf 
Network for Public Health Law. (n.d.). Legal interventions to reduce overdose mortality: 
Naloxone access and overdose Good Samaritan laws. Retrieved from 
https://www.networkforphl.org/_asset/qz5pvn/legal-interventions-to-reduce-
overdose.pdf 
North Carolina Harm Reduction Coalition. (n.d.). US Law enforcement who carry 
naloxone. Retrieved from http://www.nchrc.org/law-enforcement/us-law-
enforcement-who-carry-naloxone/ 
O’Donnell, J. K., Gladden, R. M., Mattson, C. L., & Kariisa, M. (2018). Notes from the 
field: Overdose deaths with carfentanil and other fentanyl analogs detected — 10 
States, July 2016–June 2017. MMWR. Morbidity and Mortality Weekly 
Report, 67(27), 767–768. doi:10.15585/mmwr.mm6727a4 
O’Donnell, J. K., Gladden, R. M., & Seth, P. (2017). Trends in deaths involving heroin 
and synthetic opioids excluding methadone, and law enforcement drug product 
reports, by census region — United States, 2006–2015. MMWR: Morbidity and 
Mortality Weekly Report, 66(34), 897–903. doi:10.15585/mmwr.mm6634a2 
Olfson, M., Wall, M., Wang, S., Crystal, S., & Blanco, C. (2018). Risks of fatal opioid 
overdose during the first year following nonfatal overdose. Drug and Alcohol 
Dependence, 190, 112–119. doi:10.1016/j.drugalcdep.2018.06.004 
144 
 
Pade, P., Fehling, P., Collins, S., & Martin, L. (2017). Opioid overdose prevention in a 
residential care setting: Naloxone education and distribution. Substance 
Abuse, 38(1), 113–117. doi:10.1080/08897077.2016.1176978 
Panther, S. G., Bray, B. S., & White, J. R. (2017). The implementation of a naloxone 
rescue program in university students. Pharmacy Today, 57(2), S107–S112. 
doi:10.1016/j.japh.2016.11.002 
Papp, J., & Schrock, J. (2017). Take-home naloxone rescue kits following heroin 
overdose in the emergency department to prevent opioid overdose-related repeat 
emergency department visits, hospitalization, and death: A pilot study. Annals of 
Emergency Medicine, 70(4), S170. doi:10.1016/j.annemergmed.2017.07.315 
Parab, S., & Bhalerao, S. (2010). Choosing statistical test. International Journal of 
Ayurveda Research, 1(3), 187–191. doi:10.4103/0974-7788.72494 
Pound, P., & Ritskes-Hoitinga, M. (2018). Is it possible to overcome issues of external 
validity in preclinical animal research? Why most animal models are bound to 
fail. Journal of Translational Medicine, 16(1), 1–8. doi:10.1186/s12967-018-
1678-1 
Prabhu, A., Abaid, B., Khaleel, M. S., Naik, S., Lippman, M., & Lippman, S. (2017). The 
naloxone option. Journal of Family Practice, 67(5), 288. Retrieved from 
https://www.mdedge.com/jfponline 
Queirós, A., Faria, D., & Almeida, F. (2017). Strengths and limitations of qualitative and 




Rando, J., Broering, D., Olson, J. E., Marco, C., & Evans, S. B. (2015). Intranasal 
naloxone administration by police first responders is associated with decreased 
opioid overdose deaths. American Journal of Emergency Medicine, 33(9), 1201–
1204. doi:10.1016/j.ajem.2015.05.022 
Rasia-Filho, A. A., Londero, R. G., & Achaval, M. (2000). Functional activities of the 
amygdala: An overview. Journal of Psychiatry and Neuroscience, 25(1), 14–23. 
Retrieved from https://jpn.ca/ 
Ray, B. R., Lowder, E. M., Kivisto, A. J., Phalen, P., & Gil, H. (2018). EMS naloxone 
administration as non-fatal opioid overdose surveillance: 6-year outcomes in 
Marion County, Indiana. Addiction, 113(12), 2271–2279. doi:10.1111/add.14426 
Rogers, E. M. (2002). Diffusion of preventive innovations. Addictive Behaviors, 27(6), 
989–993. doi:10.1016/S0306-4603(02)00300-3 
Rogers, E. M. (2003). Diffusion of innovations (5th ed.). New York, NY: Free Press. 
Rowe, C., Santos, G.-M., Vittinghoff, E., Wheeler, E., Davidson, P., & Coffin, P. O. 
(2015). Predictors of participant engagement and naloxone utilization in a 
community-based naloxone distribution program. Addiction, 110(8), 1301–1310. 
doi:10.1111/add.12961 
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016). Increases in drug and opioid-
involved overdose deaths — United States, 2010–2015. MMWR: Morbidity and 




Rudestam, K. E., & Newton, R. R. (2015). Surviving your dissertation: A comprehensive 
guide to content and process (4th ed.). Thousand Oaks, CA: Sage. 
Rudski, J. (2016). Public perspectives on expanding naloxone access to reverse opioid 
overdoses. Substance Use and Misuse, 51(13), 1771–1780. 
doi:10.1080/10826084.2016.1197267 
Samuels, E. A., Bernstein, S. L., Marshall, B. D. L., Krieger, M., Baird, J., & Mello, M. 
J. (2018). Peer navigation and take-home naloxone for opioid overdose 
emergency department patients: Preliminary patient outcomes. Journal of 
Substance Abuse Treatment, 94, 29–34. doi:10.1016/j.jsat.2018.07.013 
Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2019). Drug and opioid-
involved overdose deaths — United States, 2013–2017. MMWR. Morbidity and 
Mortality Weekly Report, 67(51 & 52), 1419–1427. 
doi:10.15585/mmwr.mm675152e1 
Seither, J., & Reidy, L. (2017). Confirmation of carfentanil, U-47700 and other synthetic 
opioids in a human performance case by LC-MS-MS. Journal of Analytical 
Toxicology, 41(6), 493–497. doi:10.1093/jat/bkx049 
Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018). Overdose deaths involving opioids, 
cocaine, and psychostimulants — United States, 2015–2016. MMWR: Morbidity 
and Mortality Weekly Report, 67(12), 349–358. doi:10.15585/mmwr.mm6712a1 
Sherman, S. G., Gann, D. S., Tobin, K. E., Latkin, C. A., Welsh, C., & Bielenson, P. 
(2009). “The life they save may be mine”: Diffusion of overdose prevention 
147 
 
information from a city sponsored programme. International Journal on Drug 
Policy, 20(2), 137–142. doi:10.1016/j.drugpo.2008.02.004 
Stewart, M. S., & Hitchcock, J. H. (2016). Quality considerations. In G. J. Burkholder, K. 
A. Cox, & L. M. Crawford (Eds.), The scholar-practitioner’s guide to research 
design. Baltimore, MD: Laureate Publishing. 
Szklo, M., & Nieto, F. J. (2014). Epidemiology: Beyond the basics (3rd ed.). Sudbury, 
MA: Jones and Bartlett. 
Trochim, W. M. K., & Donnelly, J. P. (2008). The research methods knowledge base (3rd 
ed.). Mason, OH: Cengage Learning. 
Undersander, M. A., Kettler, R. M., & Stains, M. (2017). Exploring the item order effect 
in a geoscience concept inventory. Journal of Geoscience Education, 65(3), 292–
303. doi:10.5408/16-235.1 
Upadhyay, J., Maleki, N., Potter, J., Elman, I., Rudrauf, D., Knudsen, J., … Borsook, D. 
(2010). Alterations in brain structure and functional connectivity in prescription 
opioid-dependent patients. Brain, 133, 2098–2114. doi:10.1093/brain/awq138 
U.S. Department of Commerce, U.S. Census Bureau. (n.d.). QuickFacts: Tennessee. 
Retrieved from 
https://www.census.gov/quickfacts/fact/table/TN/PST045219#PST045219 
U.S. Department of Health and Human Services, National Institutes of Health, National 




U.S. Department of Health and Human Services, National Institutes of Health, National 
Institute on Drug Abuse. (n.d.-b). Opioid summaries by state. Retrieved from 
https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state 
U.S. Department of Health and Human Services, National Institutes of Health, National 
Library of Medicine. (n.d.-a). Compound summary: Carfentanil. Retrieved from 
https://pubchem.ncbi.nlm.nih.gov/compound/62156 
U.S. Department of Health and Human Services, National Institutes of Health, National 
Library of Medicine. (n.d.-b). Dailymed. Retrieved from 
https://dailymed.nlm.nih.gov/dailymed/index.cfm 
U.S. Department of Health and Human Services, Office of the Surgeon General. (2018). 
U.S. Surgeon General’s advisory on naloxone and opioid overdose. Retrieved 
from https://www.hhs.gov/surgeongeneral/priorities/opioids-and-
addiction/naloxone-advisory/index.html 
U.S. Department of Health and Human Services, Substance Abuse and Mental Health 
Services Administration. (2018). Key substance use and mental health indicators 
in the United States: Results from the 2017 National Survey on Drug Use and 
Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). Rockville, 
MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and 
Mental Health Services Administration. Retrieved 
from https://www.samhsa.gov/data/ 




Vivolo-Kantor, A. M., Seth, P., Gladden, R. M., Mattson, C. L., Baldwin, G. T., Kite-
Powell, A., & Coletta, M. A. (2018). Vital signs: Trends in emergency department 
visits for suspected opioid overdoses — United States, July 2016–September 
2017. MMWR: Morbidity and Mortality Weekly Report, 67(9), 279–285. 
doi:10.15585/mmwr.mm6709e1 
Volpe, D. A., Tobin, G. A. M, Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., ... 
Verbois, S. L. (2011). Uniform assessment and ranking of opioid Mu receptor 
binding constants for selected opioid drugs. Regulatory Toxicology 
Pharmacology, 59(3), 385–390. doi:10.1016/j.yrtph.2010.12.007 
Wagner, K. D., Bovet, L. J., Haynes, B., Joshua, A., & Davidson, P. J. (2016). Training 
law enforcement to respond to opioid overdose with naloxone: Impact on 
knowledge, attitudes, and interactions with community members. Drug and 
Alcohol Dependence, 165, 22–28. doi:10.1016/j.drugalcdep.2016.05.008 
Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-
Alawad, A., … Ozonoff, A. (2013). Opioid overdose rates and implementation of 
overdose education and nasal naloxone distribution in Massachusetts: Interrupted 
time series analysis. British Medical Journal, 346, f174. doi:10.1136/bmj.f174 
Warfield, S., Pollini, R., Stokes, C. M., & Bossarte, R. (2019). Opioid-related outcomes 
in West Virginia, 2008–2016. American Journal of Public Health, 109(2), 303–
305. doi:10.2105/AJPH.2018.304845 
Warner, R. M. (2013). Applied statistics: From bivariate through multivariate techniques 
(2nd ed.). Thousand Oaks, CA: SAGE Publications. 
150 
 
Weaver, L., Palombi, L., & Bastianelli, K. M. S. (2018). Naloxone administration for 
opioid overdose reversal in the prehospital setting: Implications for 
pharmacists. Journal of Pharmacy Practice, 31(1), 91–98. 
doi:10.1177/0897190017702304 
Wheeler, E., Davidson, P. J., Jones, T. S., & Irwin, K. S. (2012). Community-based 
opioid overdose prevention programs providing naloxone — United States, 2010. 
MMWR: Morbidity and Mortality Weekly Report, 61(6), 101–105. Retrieved from 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6106a1.htm?s_cid=mm6106
a1_w 
Wheeler, E., Jones, T. S., Gilbert, M. K., & Davidson, P. J. (2015). Opioid overdose 
prevention programs providing naloxone to laypersons — United States, 




White House, The. (n.d.) Ending America’s opioid crisis. Retrieved from 
https://www.whitehouse.gov/opioids/ 
Williams, K., Lang, E. S., Panchal, A. R., Gasper, J. J., Taillac, P., Gouda, J., … Hedges, 
H. (2019). Evidence-based guidelines for EMS administration of naloxone, 
Prehospital Emergency Care, 1–15. doi:10.1080/10903127.2019.1597955 
151 
 
Willman, M. W., Liss, D. B., Schwarz, E. S., & Mullins, M. E. (2017). Do heroin 
overdose patients require observation after receiving naloxone? Clinical 
Toxicology, 55(2), 81–87. doi:10.1080/15563650.2016.1253846 




World Health Organization. (2015, November 4). Proposed international nonproprietary 
names, list 114. WHO Drug Information, 29(4), 467. Retrieved from 
http://apps.who.int/medicinedocs/documents/s22207en/s22207en.pdf 
World Health Organization. (2018, August). Management of substance abuse: 
Information sheet on opioid overdose. Retrieved from 
https://www.who.int/substance_abuse/information-sheet/en/ 
Xu, J., Davis, C. S., Cruz, M., & Lurie, P. (2018). State naloxone access laws are 
associated with an increase in the number of naloxone prescriptions dispensed in 
retail pharmacies. Drug and Alcohol Dependence, 189, 37–41. 
doi:10.1016/j.drugalcdep.2018.04.020. 
Zhang, X., Marchand, C., Sullivan, B., Klass, E. M., & Wagner, K. D. (2018). Naloxone 
access for emergency medical technicians: An evaluation of a training program in 





Appendix: Data Use Agreements 
 
  
153 
 
 
  
154 
 
 
  
155 
 
 
  
156 
 
 
  
157 
 
 
 
